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ABSTRACT
Nonviral gene delivery methods have been explored as the replacement o f viral
systems for their low toxicity and immunogenicity. However, they have yet to reach
levels competitive to their viral counterparts. Electroporation figured prominently as an
effective nonviral gene delivery approach for its balance on the transfection efficiency
and cell viability, no restrictions of probe or cell type, and operation simplicity. The
commercial electroporation systems have been widely adopted in the past two decades
but still carry drawbacks associated with the high applied electric voltage, unsatisfied
delivery efficiency, and/or low cell viability. What we did was to improve electroporation
performance by application of gold nanoparticles (AuNPs). By adding highly conductive
AuNPs in an electroporation buffer solution, we demonstrated an enhanced
electroporation performance (i.e., better DNA delivery efficiency and higher cell
viability) on mammalian cells from two different aspects: the free, naked AuNPs reduced
the resistance of the electroporation solution so that the local pulse strength on cells was
enhanced; targeting AuNPs (e.g., Tf-AuNPs) were brought to the cell membrane to work
as virtual microelectrodes to porate the cells with a limited area from many different
sites.
The enhancement was confirmed with leukemia cells in both a commercial batch
electroporation system and a home-made flow-through system using gWizGFP plasmid
DNA probes. Such enhancement depends on the size, concentration, and the mixing ratio

o f free AuNPs/Tf-AuNPs. An equivalent mixture of free AuNPs and Tf-AuNPs exhibited
the best enhancement with the transfection efficiency increasing 2-3 folds with minimum
sacrifice of cell viability. This new delivery concept - the combination o f nanoparticles
and electroporation technologies - could be widely applied in various in vitro and in vivo
delivery routes of nucleic acids, anticancer drugs, or other therapeutic materials. In the
second part o f this dissertation, we further demonstrated its success in the enhancement
of polyplex delivery o f DNA. Specifically, AuNPs were used to carry polyplex (a
chemical approach) while electroporation (a physical approach) was applied for fast and
direct cytosolic delivery. AuNPs o f various sizes were first coated with polyethylenimine,
which were further conjugated with DNA plasmids to form AuNPs-polyplex. The hybrid
nanoparticles were then mixed with cells and introduced into cell cytosol by
electroporation.
In this hybrid approach, cationic polymer molecules condense and/or protect
genetic probes, while AuNPs help fix polycations to reduce their cytotoxicity and
promote the transfection efficiency of electroporation. The delivery efficiency was
evaluated with model adherent cells (i.e., NIH 3T3) and suspended cells (i.e., K562)
together with their impact on cell viability. We found that AuNP-polyplex showed 1.5-2
folds improvement on the transfection efficiency with no significant increase of toxicity
when compared to free plasmid delivery by electroporation alone. Such a combination of
physical and chemical delivery concepts may be further developed for the delivery of
various therapeutic materials for both in vitro and in vivo applications. Thirdly, we tried
nanoparticle enhanced delivery of small nucleotide including siRNA and miRNA as
further proof o f our concept. AuNPs are used to enhance the strength of the local electric

V

field and conjugated with the polyplex to reduce the cytotoxicity. The RNA release,
expression, and their effect in regulating the target genes were justified.
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CHAPTER 1
INTRODUCTION
1.1
1.1.1

Research Hypothesis

Central Problems
A variety o f non-viral strategies are becoming favorable alternatives to viral

transduction, having a low risk o f oncogenesis and inflammation [1,2]. Potent
therapeutic molecules are condensed or protected by cationic polymer or lipid via
forming complexes (e.g. polymer-DNA complexes, lipo-DNA complexes) which help
overcome multiple delivery barriers. Several molecules or probes, including plasmids,
oligonucleotides, ribozymes, or small interfering RNAs, have been successfully tested
with these strategies [3-15]. However, many o f them showed slow and inefficient cellular
uptake, high cytotoxicity, and/or low expression efficiency.
Simultaneously, physical gene delivery methods, electroporation in particular,
have been explored with attractive features including surgery-like treatment, quick
delivery response, and almost no restrictions on cell type and exogenous material
properties. They have been widely used to reveal biological functions and transport at
cellular level as well as to facilitate the delivery o f various molecular probes.
Conventional electroporation has been reasonably successful, but it has several major
drawbacks, including high required voltages, large DNA consumption, low transfection
efficiency, and/or cell viability.
1

2

1.1.2

Objectives
We hypothesized that the application o f gold nanoparticles (AuNPs) in

electroporation could improve the transfection performance of both electroporation and
polyplex mediated DNA and RNA delivery strategies. With high conductivity, AuNPs
could significantly reduce the potential drop consumed between the two electrodes
needed in electroporation, and the local pulse strength on cells is highly focused. After
tagging targeting molecules, AuNPs are brought to the cells to further limit the pulse
induced polarization area within tiny spots on the cell membrane. In this way, the
temporary permeable openings during electroporation will be greatly increased in number
with each a limited size. This helps the following cell membrane recovery and the
eventual cell survival rate.
Besides the enhancement of gold nanoparticles on electroporation, we also looked
into their contribution to polyplex delivery. Because o f their monodispersed size and
consistent surface area and charge, gold nanoparticles help control the payload o f cationic
polymer on individual particles and the dimensions of hybrid polyplex nanoparticles.
Together with good protection o f DNA and RNA probes in the serum, such hybrid
structure helps minimize the free cationic polymers in polyplex samples and fix those
dissociated ones during cytoplasmic release. As captured cationic molecules are found to
be much less toxic to their free counterparts; this help reduce die common cytotoxicity
issues associated with polyplex delivery [16]. Because o f the presence of AuNPs,
electroporation is also adopted to promote direct cytoplasmic delivery of polyplex to
bypass the traditionally slow and inefficient endocytosis-mediated delivery route of the
polyplex.

1.2

Approaches

Based on these hypotheses, AuNPs with various sizes and aspect ratios were
applied in electroporation. AuNPs conjugated with transferrin (AuNPs-Tf) of various
ratios were mixed with cells before electroporation. AuNPs-Tf were prepared by
incubating AuNPs with transferrin that was thiolated by Traut’s reagent (Figure 1-1).
This helps bring AuNPs to cells via conjugation o f transferrin with transferrin receptors
(TfR) on the cell membrane. The enhancement was evaluated in both a commercial batch
electroporation system and a home-made flow-through system.

^ Sv^

NH2 Cl

Traut's Reagent

+

r

- nh 2

Primary Amine
Molecule

Modification Producing a
Terminal Sulfhydryl Group

Figure 1-1: Reaction scheme of Traut’s Reagent with molecules containing primary
amines.
Polyethyliemine (PEI) was fixed on AuNPs by electrostatic interactions
(AuNPs/PEI) via incubation of AuNPs and free PEI solution. The original citric acid
terminated surface o f AuNPs facilitates the deposition o f PEI molecules through
electrostatic interactions. Negatively charged DNA/RNA probes were conjugated to
AuNPs/PEI to form AuNPs-polyplex.
We evaluated these hypotheses and concepts with model systems with DNA/RNA
delivery to both adherent (e.g., NIH 3T3) and suspended cells (e.g., K562). The delivery
enhancement was evaluated by measuring the cell viability and transfection efficiency of
DNA and RNA probes.

4
1.3

Structure

Chapter 1 introduces the central problems and objectives for this research projectthe research approaches and the organization of this dissertation are shown. Chapter 2
provides a literature review on relevant research work involving electroporation,
polyplex, and other nanoparticles based DNA and RNA delivery. Chapter 3 demonstrates
free and transferrin-grafted AuNPs enhanced electroporation in mammalian cell
transfection. Chapter 4 demonstrates the advantage of AuNPs electroporation enhanced
polyplex delivery to mammalian cells. Chapter 5 describes the AuNP enhanced RNA
delivery to mammalian cells. Chapter 6 concludes the results of the dissertation and
recommends some work worthy o f further exploration.

CHAPTER 2
LITERATURE REVIEW

2.1
2.1.1

Motivations

Genetic Therapy for Diseases
In September of 1990, a four-year old girl with adenosine deaminase (ADA)

deficiency became the first gene therapy patient at the NIH clinical center [17].
Thereafter, gene therapy has become the research focus in many pharmaceutical, medical,
biochemical and chemical labs over the world. In general, the technique of gene therapy
includes identifying suitable nucleic acid sequences and cell types, as well as developing
feasible methods to deliver enough genetic probes into these cells, while the therapeutic
range involves the diagnosis of genetic diseases, depression of tumor development,
fighting against viral infections, and so forth. During the last 30 years, hundreds o f gene
therapy studies have been conducted, while more and more efforts (more than 70%) o f
genetic therapy were steered to cancer-related research [18].
Cancer development usually involves multiple alterations on the gene level o f
cancer cells [19]. The balance between oncogenes and tumor suppressor genes plays a
pivotal role in carcinogenesis. The oncogenes facilitate cell proliferation, while tumor
suppressor genes program apoptosis. Based on this understanding, anti-oncogenes and
apoptosis related genes are usually used in cancer treatments.

5

6

Among various therapeutic strategies, how to deliver genes efficiently remain one
o f the major challenges. Naked nucleic acids could be successfully delivered into tumors
[20,21]; however, they can be easily cleared out and gain poor efficiency for systematic
delivery [22]. Therefore, exogenous gene vehicles are needed with the purpose o f
protection. In general, those gene vehicles could be categorized as two groups: viral and
non-viral systems. The viral delivery systems exhibit high efficiency while they also
carry obvious limitations: viral vectors would be confronted by host immune responses
and the size o f inserted genetic materials is also limited by the carrier capacity [23]. The
non-viral systems can avoid these limitations, while their delivery efficiency is not yet
competitive to their viral counterparts.
2.1.2

Virus Vectors in Gene Delivery
In virus-mediated gene delivery, several viral vectors are popular, including

retrovirus, adenovirus, herpes simplex virus (HSV), and adeno-associated virus (AAV).
Retroviruses are small RNA viruses with DNA intermediate. They are developed by
replacing the vital viral genes with therapeutic ones, which will be integrated into the
host genome. Despite their high transfection efficiency, most retroviruses only infect
actively dividing cells. This makes them not work well with tumors as all tumors contain
some non-dividing or resting cells [21,24], Adenoviruses are viruses which carry double
strands of DNA. They could infect both dividing and non-dividing cells. However, their
transfection is transient since they cannot integrate into the host cell genome. Therefore,
repetitive treatment is generally needed [25-27]. HSVs are usually utilized to deliver
genes into brain tumors since they infect the ending o f sensory nerves and migrate to the
neuronal cells [28,29]. AAVs can infect both dividing and non-dividing cells as
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adenoviruses, while integrating into the host genome like retroviruses. AAVs are less
toxic than other virus vectors, but they usually need helper viruses which may bring
contamination problems [30-32],
2.2

Polymers in Gene Delivery

Recent research interest in the field of gene delivery has been shifted greatly from
viral vectors to non-viral systems because o f the associated vector size limitation and
immunogenicity issues. Among those non-viral transfection systems, cationic polymerbased polyplex nanoparticles are attracting much attention with acceptable efficiency and
biocompatibility.
2.2.1

Polv-L-lvsine
Poiy-L-lysine (PLL) is a natural cationic polymer that has been widely used as

genetic probe carrier in early polyplex synthesis. The size of PLL in the polyplex
composition ranges from less than 20 to more than 1000 amine groups, typically with a
size o f less than 100 nm [33-39]. The main role o f PLL in polyplex is to condense
negatively charged molecules (DNA or RNA) and bind proteins as target ligands. In
1989, Wu et al. reported the modification o f PLL with asialoorosomucoid (ASOR) which
targets liver specific receptors, resulting in organ specific drug delivery [40], In 1998,
Schaffer et al. conjugated PLL with epidermal growth factors (EGF), enabling delivery to
cells expressing EGF receptors [41], Thereafter, several ligands have been used to modify
PLL [42-44],
Nevertheless, the application of PLL polyplexes has been limited because o f its
poor stability in vivo [44-46]. Protein binding and salt aggregation might be the reasons
for the rapid clearance o f PLL polyplexes from blood [43,47], Ward et a l showed that
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poor solubility, leukocyte stimulation, macrophage capture and complement activation
might also contribute to poor blood circulation o f PLL polyplexes [48], To improve the in
vivo performance o f PLL conjugates, PEG modification was performed to form a shell
protecting polyplexes from proteins [49, 50]. The molecular weight of PLL has also been
considered as a factor which influence its stability. Larger molecular weight resulted in
better stability in blood and higher expression level [43,48],
2.2.2

Polvethvlenimine
Polyethylenimine (PEI) is a synthesized cationic polymer that could

electrostatically conjugate negatively charged nucleic acids with primary amine groups.
PEI could be synthesized as linear or branched with various molecular weight (e.g., 2 ,4 ,
25,50,70, 800 kDa). PEI can facilitate the endosomal escape based on its buffering
capacity. The osmosis swelling happens when pH drops in PEI containing endosomes,
which is the so-called “proton sponge effect”, resulting in release of PEI-nucleic acids
complexes into cytoplasm [4, 51, 52]. Research has demonstrated that the transfection
efficacy and cytotoxicity depend on molecular weight, compactness and modification of
PEI [53, 54],
The traditional method of PEI-polyplex preparation is a simple bulk mixing
process in which the adding order of reagents greatly influences the transfection
efficiency. It has been demonstrated that adding the PEI solution to the plasmid solution
results in 10-fold more efficiency than the opposite [4, 55]. The reason is that a single
copy o f plasmid is complexed into a polyplex when plasmid is added to the PEI solution,
whereas multiple copies of plasmids are incorporated into a polyplex in the opposite
mixing order. Another consideration is the so-called “N/P ratio”, which is the ratio o f the
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molar ratio of nitrogen in the PEI to the phosphate in the nucleic acid. Studies have
shown that plasmid is poorly condensed at N/P ratio around 3.3 leading to low
transfection efficiency. Better efficiency could be achieved with an increase of N/P ratio;
however, cell viability would be sacrificed [54, 56], In our previous study, cytotoxicity
became increasingly significant while N/P ratio was above 6.6 [57-61],
Aside from being an independent delivery vehicle, PEI is also used to coat other
nanoparticles to improve their transfection performance. Duan et al. studied the
complexation o f PEI with quantum dots to deliver plasmids, and PEI (linear and branched
with molecular weight of 0.423, 0.6 - 0.8,1.2, 1.8 - 2, and 10-25 kDa) was chosen to
enhance particle uptake and facilitate endosomal escape [62]. Xia et al. modified the
surface o f mesoporous silica nanoparticles with PEI and much higher affinity with
nucleic acids was observed. The cellular uptake o f those PEI coated particles was found
significantly enhanced, which enabled efficient delivery and a more satisfied expression
[63]. Several studies have also been done with PEI-coated magnetic particles. They were
either synthesized in a PEI solution or mixed with it, resulting in covalent or electrostatic
binding to PEI molecules. All of these strategies promoted gene delivery [64-68].
Besides magnetic particles, PEI coating o f gold nanoparticles has also attracted
great attention in recent years. Gold nanoparticle had already been used to deliver nucleic
acids directly into the cells [69-73], Elbakry et al. introduced a layer-by-layer strategy
which provided a promising solution to the aggregation problem when AuNPs were
assembled with nucleic acids [74]. Song et al. reported a new, simple method to prepare
PEI-capped AuNPs by directly mixing HAuCU solution with PEI [75]. The delivery of
siRNA with these complex nanoparticles showed much higher efficiency and cell
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viability compared to that when delivered with PEI alone. All of these studies indicate
that the combination o f PEI with AuNPs has great potential in gene delivery.
2.2.3

Chitosan
Chitosan is a biopolymer which is naturally produced by deacetylation o f long-

chain polymer, chitin [76, 77]. It is composed o f two subunits, N-acetyl-glucosamine and
D-glucosamine linked by [J(l, 4)-glucosidic bonds. The amine groups in N-acetylglucosamine subunits, with a pKa value o f around 6.5, provide high positive charge
density from an acidic to a neutral pH range [78, 79], Studies have shown that chitosan
has good biocompatibility as well as the ability to increase the permeability o f the cell
membrane [80-82], These properties enable chitosan as a favorable carrier for gene
delivery.
Mumper et a l first reported the application of chitosan as a plasmid delivery
carrier [83]. Thereafter, interests in chitosan have increasingly risen. Roy et a l prepared
chitosan/DNA nanoparticles with diameters o f 200-300 nm and successfully transfected
HEK293 cells [84]. Richardson et al. demonstrated the protection effect o f chitosan to
plasmids from DNase in vitro [85]. There are also other studies on derived or modified
chitosan for targeted transfection [86, 87],
Despite the gene condensation and protection functions, the transfection
efficiency o f chitosan complexes is relatively low [88], The degree o f acetylation and
molecular weight o f chitosan are the two main factors that influence its transfection
efficiency. Some studies have already shown that plasmid binding efficacy and cellular
uptake o f chitosan complexes decreased with decreasing acetylation [89-92], The
influence o f molecular weight could be explained by the chain entangle effect: the higher
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the molecular weight, the easier for chitosan to entangle the free plasmids. As a result,
chitosan with lower molecular weight is less efficient at conjugating and protecting
plasmids, resulting in a low transfection [89,92],
2.2.4

Polyethylene Glvcol
The application o f other cationic polymers in the polyplex is limited because o f

their cytotoxicity and poor in vivo stability. Polyethylene glycol (PEG) has been widely
used as a copolymer in drug or gene delivery as an effort to overcome these limitations.
Incorporation o f PEG into polyplex formation, which is called PEGylation, has been
reported to help increase stability o f the particles, achieve extended circulation, and
protect the carried probes from enzymes [59,93-96],
Such an excellent feature of PEG is attributed to its popularity in copolymer
construction. First, shielding the positive charges o f polyplexes with PEG lowers the
cytotoxicity and reduces the degradation of conjugated probes. The polymer-DNA/RNA
complex is generally prepared with excess cationic polymers, which leads to a net
positive charge. While it facilitates cellular uptake by interacting with negatively charged
cell membrane, the high concentration o f positively charged polyplex could induce
cytotoxicity. At the same time, intracellular proteins could bind to the polyplex, resulting
in rapid clearance and lower the delivery efficiency [47, 59,97]. Kataoka et al. studied
PEG-PLL block copolymer; the result showed that DNA was stable in vitro with the
presence of DNase I in more than 60 min, while the transfection o f DNA with this
copolymer was higher than that with PLL only. In the in vivo tests with PEG-PLL
complex, exogenous DNA was detected in the blood 30 min after the injection, while
naked DNA was found degraded in 5 min [49,98-100]. Petersen et al. investigated the
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PEGylation of PEI and greatly reduced the cytotoxicity of PEI even if the transfection
efficiency was not improved much [101]. Modifying the surface charge o f nanoparticles
with PEG could increase the water solubility since polymer-DNA/RNA complexes are
kind o f water resistant in their charge neutralized state [102]. A PEG-PLL dendrimer,
synthesized by Choi etal. demonstrated that the water solubility o f PEG-PLL-DNA
complex was higher than PLL/DNA because o f the introduction o f PEG [103]. PEG
could work as a molecule spacer between polymers and ligands to assist the binding of
ligands to their receptors. Successful examples include the use of peptide conjugated
PEG-PEI, lipoprotein conjugated PEG-PLL and folate conjugated PEG-PLL [104-106],
In spite o f these advantages of PEG in polyplex formulation, some studies have
shown that PEGylation reduced cellular uptake and decreased gene expression [93,107,
108], To minimize this negative influence of PEG, some cleavable copolymer
configurations were further synthesized and explored [95,109-112].
2.3
2.3.1

Application of Gold Nanoparticles in Gene Delivery

Historic Introduction
AuNPs are most stable nanoparticles with many favorable chemical and physical

properties. This enables their applications in material science, electronics, or biomedical
research. The extraction o f gold started around the 5th century, and the early application
of gold colloid was to make ruby glass or color ceramics. In 1857, Michael Faraday
reported the reduction of an aqueous AuCl4" with phosphorus in CS 2 to form colloid gold
which was of a deep red color [113]. However, the term “colloid” was not proposed until
1861 by Graham [114], Various methods in the preparation o f gold colloids were
reported in the last century [115-127], In the past twenty years, gold colloids (or AuNPs)
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have attracted much attention as a non-viral drug or gene delivery carriers because o f
their good biocompatibility, large area volume ratio, controllable size and shape, and
other favorable properties [69, 116, 128-143].
2.3.2

Synthesis and Modification of Gold Nanoparticles
The ease o f surface modification led to an exciting development of AuNPs

application in gene delivery. One o f the most popular surface modifications of AuNPs is
the citrate functionalization. Citrate-capped AuNPs could be steadily prepared with
diameter ranges from 5 nm to 250 nm [116, 144], Based on this well-established
technique, studies investigated the relationship between the particle sizes and cell uptake.
For example, Chan et al. reported that the size of the citrate-capped AuNPs did affect the
cellular uptake amount [138], Compared to AuNPs with diameters of 14 and 74 nm,
AuNPs with diameters o f 50 nm were more favorable for the internalization by HeLa
cells. They supposed the non-specific binding of citrate-capped AuNPs with proteins
contributed to the uptake [138]. Further studies also showed that binding some positively
charged proteins (e.g., transferrin) could facilitate the particle internalization via
endocytosis [137, 140], Many other research work also used citrate functionalized AuNPs
to construct more sophisticated complexes in order to increase the cellular uptake and
affect cell response or target AuNPs to specific locations [71, 132,145-147],
AuNPs o f 1-3 nm stabilized by a monolayer o f amine-terminated alkanethiolates
could be synthesized with the Brust-Schifffin method [148]. In physiological pH,
positively charged amine groups could bind negatively charged nucleic acids. Retello et
al. reported successful plasmids transfection by 2 nm AuNPs with the amine surface
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groups [132]. Thomas et al. used PEI as amine provider in AuNPs synthesis and the
resulting particles delivered plasmids more efficiently than PEI alone [69],
Other modifications of AuNPs involve the coating of peptides, antibodies and so
forth. Feldheim et al. reported the conjugation of peptides to AuNPs, showing that
peptides with both receptor-mediated endocytosis and nuclear localization signal
facilitated the entry o f AuNPs into the nucleus [147, 149, 150], El-Sayed et al.
demonstrated greater affinity o f antibody modified AuNPs to cancerous cells, which may
improve photothermal therapy [151]. In some cases, nucleic acids were thiolated for the
attachment to AuNPs surface since gold has a high affinity to thiol groups.
2.3.3

The Applications o f Gold Nanoparticles in Gene Delivery
Efficient delivery o f nucleic acids often plays an important role in the treatment of

various diseases [152, 153]. Its delivery involves the insertion o f healthy copies of DNA
or RNA probes in specific cells, which relies on either viral infection or nonviral
membrane perturbation [154], but have safety concerns associated with oncogenesis,
immunogenicity, and toxicity [2, 155]. Nonviral delivery approaches, including chemical
and physical approaches, have been explored as replacements to natural viruses, but do
not reach competitive levels to their viral counterpart [74, 143, 156-176]. Among
nonviral approaches, gold nanoparticles (AuNPs) have been extensively explored in
DNA or RNA delivery for their gold biocompatibility and unprecedented combination of
therapeutic and imaging capability [74, 143,162-165]. Through the unique gold-thiol
chemistry and/or electrostatic interactions, AuNPs help improve the cellular uptake o f
molecular probes through similar internalization routes (i.e., endocytosis) as other
nanoparticles. The long intracellular delivery barriers generally prevent many
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nanoparticles from reaching the cytosol or nucleus, with the aid o f cell penetrating
peptides (CPPs), AuNPs-siRNA nanoconjugates were successfully demonstrated to reach
cytosol directly to improve the delivery efficiency [166]. However, the low release extent
o f siRNAs ffom AuNPs still leads to poor transfection efficiency due to the high affinity
o f AuNPs and therapeutic agents [167].
2.4
2.4.1

Electroporation in Molecules Delivery

Introduction
Compared to nanoparticle-mediated delivery routes, physical approaches have

been used in the past two decades to deliver drugs or gene probes directly to the desired
intracellular locations (e.g., cytosol or nucleus) to attain impressive benefits in various
biomedical research and clinic trials [168-176], Among them, electroporation figures
prominently for their balance of simplicity, transfection effectiveness, fewer restrictions
on probe or cell type, and operation convenience [172],
Electroporation or electropermeabilization has been known for decades and
received increasing attention over the last thirty years. Electroporation is the application
o f external electric pulses to induce transient and reversible breakdown of cell
membranes to deliver a variety of molecule probes into the cells. Because it delivers drug
or genetic bypassing endocytosis and endosomal escape, much more efficient transfection
has been achieved with electroporation. The first report of reversible cell electroporation
was in 1982 [170]. Thereafter, over the last decades, electroporation has been developing
from a laboratory technique to a clinic application [174, 175,177-197],
In electroporation, transient pores are formed during electroporation, and
molecules present around the cells get access to the cytoplasm [194]. After the pulses,
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cell membranes reseal within a time scale from seconds to minutes. The membrane
breakdown is achieved when the transmembrane potential superimposed onto the resting
potential is above a threshold [198]. The transmembrane potential initiated by the
external electric field is usually estimated by:
3
bV = -rrEext cos 6[ 1 - exp(

t

)]

Eq. 2-1

where r is the radius o f the cell, Eext is the field strength, 0 is the angle between the
normal to the membrane and the direction of the field [199-202], r m is the membrane
charging time constant, given by:
rem

where a*, am and ae are conductivities o f the cytoplasm, cell membrane, and
extracellular medium, respectively, £m is the dielectric permittivity of the membrane, and
d is the membrane’s thickness [203]. Because of the “cos 6” component in Eq. 2-1,
electroporation induced permeabilization will first happen at points facing electrodes. A
theory has been established in the last century that the permeabilized area is larger at the
point facing the positive electrode and permeabilization degree is greater at the point
facing the negative electrode. Small molecules incline to diffuse into the cell via the pole
facing the positive electrode, while large, especially negative charged molecules
(electrophoretic effect is involved) prefer to enter through the pole facing the negative
electrode [204], Also indicated by Eq. 2-1, cells with a smaller radius require stronger
external electric field to trigger permeabilization, further illustrating that intracellular
organelles with a much smaller radius will not be easily permeabilized by the field, which
is just sufficient for cell membrane poration.
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2.4.2

Explanations to Electropermeabilization
The effort to illustrate the mechanism o f electroporation has been made

consequently [198,205-211]. Considerable progress o f understanding the electroporation
process has been achieved (the most popular explanation is briefly described above),
although it is far from being fully understood.
The intracellular liquid is rich in ions and therefore highly conductive. For animal
cells, the external environment (either in vitro culture medium or in vivo fluids) is also
conductive. However, the cell membrane, which is a lipid bilayer, is nonconductive and
insulates the cell inside from the outside. Therefore, two opposite charges will be
accumulated at both sides of the cell membrane when a cell is placed in an external
electric field. This condition leads to a transmembrane potential. Some reports
demonstrated that the transmembrane potential needs to be above a threshold for at least
30-40 ps to make a complete membrane structural change. There were rapid changes in
the conductivity o f the tissue in the electric fields, which might be the indication of
electropermeabilization [212,213]. Therefore, compared to “electroporation”,
“electropermeabilization” is actually a more exact term to define the change of the cell in
the electric field; the membrane permeability o f the treated cells is increased so that
otherwise non-permeant molecules (usually large or hydrophilic and cannot diffuse
across intact membranes) have a better chance o f entering into the cytoplasm [213-215].
Formation of large hydrophobic pores was the first electroporation theory
proposed by Eberhard Neumann [170]. It was confirmed later, to some extent, by some
simulation studies [216-220], Besides, several other explanations exist for the change in
permeability o f the cell membrane. Teissie et al. pointed out that the permeability change
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could result from the electrocompression force generated during the pulses with the
assumption that the force brought the two lipid layers closer and disrupted the order of
the bilayer [221], Lopez etal. demonstrated the increased permeability came from the
change in orientation of lipids polar head [222]. These explanations support the theory of
electropermeabilization without the formation of pores.
2.4.3

Electrical Factors in Electroporation
According to Schwan’s equation, referring to Eq. 2-1, the strength of the external

electric field determines the surface area that could be porated [200], Afterwards, with
the increasing understanding of the dynamic structured changes in the cell membrane,
studies have examined the importance o f pulse duration [223, 224], Thereafter, many
investigators made efforts to optimize these two electrical parameters so as to maximize
the efficiency o f delivery [170, 178, 179, 181,225-228].
To date, it has been generally agreed that combinations o f high voltage (larger
than 1000 V / cm) with very short pulse duration (less than 100 ps) and low voltage
(lower than 200 V / cm) with longer pulse duration (longer than 20 ms) lead to effective
electroporation. Some studies found that the sequential use of high voltage pulses and
low voltage pulses worked even better with a possible explanation that high voltage
porated the cell membrane while low voltage facilitated gene movements via
electrophoretic forces [200,201], Satkauskas et al. also showed the advantages o f using
short high voltage pulses and long low voltages together [229, 230], Moreover, they
demonstrated that it was not necessary for plasmids to be present during the high voltage
electroporation, but they had to be involved before the low voltage pulses [229],
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For specific cell types or tissues, choices between high voltage and low voltage,
long duration and short duration, single pulse and multiple pulses, or single set, and a
combination of high voltage and low voltage are always the considerations for efficiency
transfection. These factors need to be optimized according to other conditions.
2.4.4

Non-electrical Factors in Electroporation
Non-electrical factors should also be considered when establishing electroporation

protocols because of their obvious impact on electroporation efficiency. These factors
include the type of cells, and the size and formulation o f DNA/RNA. The electroporation
performance is known as cell type dependent. Therefore, for in vitro transfection, specific
electroporation protocol has been established through trial-and-error. However, there is
little chance for in vivo studies to transfect a certain type o f cells selectively. As such,
properties and formulations o f nucleic acids consist of the main factors that impact their
delivery by electroporation.
For gene delivery, the most common property o f DNA/RNA which will directly
influence the transfection should be the sizes. In general, smaller nucleic acids enter cells
via electroporation more easily than larger ones. This size dependence explains, to some
extent, why some researchers cannot achieve the claimed efficiency with some
nucleofectors when they use larger plasmids other than the suggested ones. Another
factor that impacts gene delivery is the methylation. To date, the DNA plasmid we use in
electroporation are usually generated from Escherichia coli, which are in a high
methylation format. Spath et al. reported a negative impact of this methylation on
transfection efficiency with electroporation to lactic acid bacteria [231]. Even though no
evidence has been shown the same situation on mammalian cells, it is worthy of notice
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that methylation o f promoter or surrounding regions may induce repression in gene
expression because methylated plasmids might be restricted by methyl-dependent
restriction enzymes [232,233].
Another factor that influences transfection efficiency is the formulation o f
DNA/RNA probes, which is the solution in which nucleic acid is suspended during
electroporation. The most commonly used formulation is sodium chloride (150 mM)
[234]. Other formulations involve OptiMem and some additives. Nicol et al. reported that
formulations with the addition of glutamate had the potential to improve transfection
efficiency with electroporation [235]. Other studies showed the improvement on
electroporation performance with modified formulations [236-240]. Moreover, researches
on the relationship between cell types and formulation additives have also been
conducted [241,242].

CHAPTER 3
GOLD NANOPARTIELCE ENHANCED ELECTROPORATION IN
MAMMALIAN CELL TRANSFECTION

3.1

Introduction

Current electroporation systems have been reasonably successful while still
carrying several major drawbacks that are associated with the high applied electric
voltage and/or the lack o f uniformity o f electric pulses on all treated cells. The low
electrical conductivity o f the electroporation solution (e.g., for PBS, it is -1.5 S/m) leads
to the consumption of a large percentage of the overall applied voltage allocated on
treated cells is much lower than expected, as illustrated in Figure 3-1 A. Because o f the
physiological condition requirements, increasing the ion strength (e.g., salt concentration)
of the electroporation buffer is not allowed to avoid such additional voltage consumption.
To achieve the desired probe transfection efficiency, harsh electroporation conditions
(e.g., high-voltage pulses) are therefore necessary to ensure enough permeabilization to
the majority o f treated cells. These conditions make electroporation inevitably
accompanied with unwanted effects (e.g., strong electrochemical reactions, gas bubble
issue, and Joule heating), which are harmful to the survival o f treated cells [175], Current
protocols are often established on the compromise between acceptable transfection
efficiency and cell viability. The recent introduction of microtechnology in
electroporation research is devoted to the reduction o f these issues through closely
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patterning electrode pairs [182-193,243-247], However, these designs often sacrifice
some favorite features o f electroporation systems, namely simplicity, low-cost, and
operation convenience.
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Figure 3-1: Schematic illustration on the mechanism of AuNPs enhancement on
electroporation: (A) The pulse enhancement effect through minimizing the electric
voltage consumed by the low conductive electroporation buffer during electroporation.
By adding highly conductive AuNPs, more percentage o f the overall electric voltage
across the two electrodes is allocated on cells to have focused pulses when compared
to the use of electroporation buffer alone; (B) localized electroporation when AuNPs
are brought to the cell membrane through affinity binding with receptors there. The
electric field is converged on the conductive AuNPs, and these AuNPs could serve as
virtual electrodes to polarize only a limited area on the cell membrane when they stay
nearby.
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Here, we present a simple approach to enhance the transfection performance o f
electroporation that is compatible to most commercial electroporation instruments as well
as the emerging micro/nanoelectroporation systems. In this new approach, free
therapeutic probes (e.g., DNA plasmids) are directly introduced into cell cytosol through
electroporation while AuNPs are added to locally enhance the electric pulse strength and
control the poration area on the cell membrane with minimum operation changes.
Because o f the high conductivity of AuNPs (~4.5* 106 S/m), the electric voltage
consumed by it is greatly reduced so that most o f the applied electric voltage is imposed
on the cells. In addition, as the electric pulses converge in the vicinity of AuNPs, the
particles work like many virtual microelectrodes when they are near the cells, with the
focused field strength causing localized poration, as shown in Figure 3-IB. In contrast to
bulk electroporation, where two large breakdown locations occur at the two poles o f the
cells facing the electrodes, electroporation with added nanoparticles is expected to cause
multiple small poration sites on the cell membrane by AuNPs. The increased number of
sites could benefit not only the recovery o f the cell membrane and the survival of the
cells, but also the uptake opportunity for the subjected probes from multiple sites.
To test our hypothesis on pulse focusing and localization effects of AuNPs, we
added AuNPs to the electroporation solution, together with mammalian cells and DNA
plasmids. Cells were then electroporated using both commercial bath-type electroporator
(BTX 830 from Harvard Apparatus) and a home-made semi-continuous flow
electroporator (SFE) [190,247]. The pulse strength focusing was evaluated from two
aspects: (i) electroporate cells in the presence of AuNPs under standard electroporation
conditions, in which the cell viability should get worse as the electric pulse is focused by
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AuNPs and cells received higher-than-optimal electric pulses; (ii) electroporate under
less-effective conditions (i.e., low-voltage, more benign pulses), in which the focusing
effect helps gain sufficient electrical strength for better transfection efficiency and/or cell
viability. Human chronic leukemia cell line (K562 cells), a hard-to transfect cell line, was
utilized in this investigation so that the localized electroporation with controlled
polarization area and locations on the cell membrane could also be conveniently
evaluated through ligand-receptor affinity binding. The electroporation enhancement
evaluation was focused on the cell viability and transfection efficiency of a reporter gene
(gWizGFP). Similar enhancement performance was also observed in NIH 3T3 cells,
confirming the effectiveness o f the enhancement roles AuNPs play in electroporation for
both adherent and suspended cell lines.
3.2
3.2.1

Materials and Methods

Materials and Reagents
AuNPs o f 5 nm, 10 nm, and 20 nm were obtained from Sigma-Aldrich. The

concentration of IX AuNPs refers to the stock solution, which has 0.01 wt% of Au (0.1
mg/ml) while the particle number varies with the size of AuNPs. Other concentrations of
AuNPs were prepared by either concentrating or diluting from the stock solution. DNA
plasmids with gWiz™GFP reporter were purchased from Aldevron, Inc. The plasmids
are driven by modified cytomegalovirus promotor that is followed by the intron A from
human CMV early gene and terminated by a highly efficient artificial transcription
terminator. All other chemicals were purchased from Sigma-Aldrich and the cell culture
reagents were purchased from Life Technologies (Carlsbad, CA) unless specified.

25
3.2.2

Cell Culture
K562 lymphoblast cells were also obtained from American Type Cell Culture

(ATCC, Manassas, VA). K562 cells were cultured and maintained in R P M I1640 media
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin,
100 g/mL streptomycin, and L-glutamine. For subculture, the desired amount of K562
cell suspension was transferred to a new Petri dish with the addition of the appropriate
amount o f fresh culture medium. All cultures were maintained at 37 °C with 5% CO2 and
100% relative humidity.
NIH 3T3 cells were obtained from American Type Cell Culture (ATCC,
Manassas, VA). They were grown and maintained in high-glucose DMEM supplemented
with 10% newborn calf serum, 1% penicillin and streptomycin, 1% L-glutamine, and 1%
sodium pyruvate. For subculture, culture medium was removed and discarded first. The
cell layer was briefly rinsed with DPBS to remove the serum, which contains trypsin
inhibitor. Then 1-2 mL trypsin-EDTA was added to a 100 cm2 Petri dish. Cell culture
was then observed under an inverted microscope until the cell layer was dispersed
(usually 5-15 min). Eight to 9 mL complete growth medium was added and cells were
aspirated by gently pipetting. An appropriate aliquot o f the cell suspension was
transferred to a new culture dish with addition o f more growth medium to make a total
volume o f 10 mL for 100 cm2 surface.
3.2.3

Thiol Modification o f Transferrin
The desired amount of transferrin in 50 mM PBS buffer (with 5 mM EDTA, pH

8.0) was dissolved to make a concentration of 10 mg/mL. EDTA in PBS helps chelate
divalent metals (e.g., Ca, Mg) in the solution, preventing the oxidation o f sulfhydryls.
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The Traut’s Reagent was dissolved in deionized water to prepare the stock solution at a
concentration o f 2 mg/mL or 14 mM; 46 pL Traut’s Reagent stock solution was added to
the transferrin solution (ten folds molar excess of the protein solution) and the mixture
was incubated for lh at room temperature. Then the solution was transferred to a dialysis
cartridge (EMD Millipore, Amicon cartridge, Cat no. UFC805024) and centrifuged at a
speed o f 4,000 * g for 20 min * 2. The thiolated transferrin was collected from the top
retentate by washing off with 50 mM PBS-EDTA solution, sterilized using 0.22 pm
Whatman filters, and stored in an aliquot at 4 °C.
3.2.4

Preparation o f Transferrin-AuNPs
500 pL of AuNPs aliquot of a desired size was centrifuged at 15,000 * g for 10

min and supernatant was discarded. The AuNPs pellet was collected and dispersed in
PBS (pH 7.4) to prepare AuNPs solutions o f desired concentrations (0.001-0.1 mg/mL).
The prepared AuNPs solution was mixed with sterilized thiolated transferrin solutions
and incubated at 4 °C overnight. Then excess transferrin was removed by repeated
centrifuge at 15,000 * g for 10 min. The purified Tf-AuNPs solution was re-diluted in
250 pL HBS solution and immediately used or stored at 4 °C in aliquot.
3.2.5

Electroporation with Naked AuNPs
NIH 3T3 cells or K562 cells were counted using hemocytometer to determine cell

density, pelleted by centrifuging at 200 x g for 5 min and then resuspended in fresh
GIBCO OPTI-MEMI (a serum free medium) at desired densities of 0.5 * 106 - 0.5 x 107
cells/mL. Cell suspensions were then mixed with naked AuNPs of various concentrations
(0.01 - 1.0 mg/mL) and sizes (5,10, and 20 nm) along with 25 pg DNA. Electroporation
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with a commercial instrument (ECM 830, Harvard Apparatus) was done in
electroporation cuvettes with a 2-mm gap, each containing a 100 pL sample solution.
Here, the pulse strength focusing was evaluated from two aspects: (1)
electroporate cells / AuNPs mixture at a standard electroporation protocol (single 10 ms
pulse o f 125 V/2 mm cuvette), in which the cell viability was supposed to get worse as
the focused pulse cells received were higher than optimal; (2) electroporate cells / AuNPs
mixture at more benign conditions (single 10 ms pulse of 95 V/2 mm cuvette), in which
the focusing effect helped gain sufficient electrical strength for better transfection
efficiency and similar or better cell viability. After electroporation, samples were
transferred to 6-well cell culture plates, incubated in a fresh medium for another 24 hr,
and then harvested for analysis.
3.2.6

Electroporation with the Mixture o f Naked AuNPs/Tf-AuNPs
Cell samples were prepared with similar concentrations in GIBCO OPTI-MEMI

medium, same as in section 3.2.5. Tf-AuNPs and cells were first incubated for 0.5-4.0
hours. Immediately before electroporation, naked AuNPs were added in to obtain a total
of 100 pL o f cell suspension. The amount of naked AuNPs was adjusted to make
appropriate mixing ratios of naked AuNPs and Tf-AuNPs (e.g., ~ 50% / 50%) and total
gold concentrations (0.1 - 0.5 mg/mL) in the mixture. According to previous studies, it
takes ~4 hr of incubation to accomplish complete affinity binding of transferrin to the
transferrin receptors on the cells. For enhancement of the mixture of AuNPs / Tf-AuNPs,
cells and AuNPs were incubated for 0.5 - 4 hr to check the difference [248], The same
electroporation protocols established in section 4.2.5 were used here. After
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electroporation, samples were transferred to 6-well cell culture plates, incubated in fresh
medium for another 24 hr, and then harvested for analysis.
3.2.7

Electroporation in Flow-Through Electroporation System
Cell samples were prepared with similar concentrations in GIBCO OPTI-MEMI

medium, same as in section 4.2.5, and then pumped through the serpentine microchannel
(length x width * depth = 37.5 mm * 150 pm x 150 pm) at a prespecified flow rate (1.8
mL/h). Electric pulses (76 pulses with each at 16 V, 10 ms) were added simultaneously
through embedded Pt electrodes. In this system, cell suspension flowed through the
microchannel in which the Pt electrodes also served as two-sided walls o f the flow
channels. When cells were pumped through, electric pulses were imposed in such a way
that most cells only received one pulse inside the flow channel. This condition was
accomplished by appropriately choosing the pulse frequency and the flow rate of cell
suspension in the microchannel. Cells were then flushed out with Opti-MEM I medium
and transferred to 6-well plates which were preloaded with a cell culture medium,
incubated in a fresh medium for another 24 hr, and then harvested for analysis. Detailed
SFE operation procedure can be found in our early publication [190].
3.2.8

Determination of DNA Delivery Efficiency
The transfection efficiency o f gWiz™GFP plasmids was evaluated both

qualitatively by visualizing the number of cells with green fluorescence within a
representative area selected from the entire culture surface under an inverted fluorescence
microscope (Olympus, Japan) and quantitatively by counting cells using a four-color flow
cytometry system (FACS Calibur, BD Biosciences, CA) 24 hr post transfection. Briefly,
an amount o f 1.5 * 106 cells/mL was collected and the percentage o f GFP-positive cells
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was calculated quantitatively via flow cytometer. The unstained samples were run first to
adjust the voltage setting and compensation o f the flow cytometer. Then the tested
samples were processed by CellQuest. At least 10,000 events were collected for each
sample.
3.2.9

Measurement o f Cell Viability
The cell viability was evaluated by an MTS cell proliferation assay (Promega,

Madison, WI). Briefly, the cells in 100 pL/well of the medium were transferred to a 96well plate and incubated; 20 pi of CellTiter 96 AQueous One solution (Promega,
Madison, WI) was added to each well, and the cells were incubated at 37 °C for another 1
hr. Absorbance was measured at 492 nm on an automated plate reader (Elx 800, Biotek,
VT). Normally grown cell samples were used as negative control whose viability was set
to 100%. Data points were represented as the mean ± standard deviation (SD) of
triplicates, unless otherwise indicated.
3.2.10

AuNPs Imaging and Tracking In Vitro
The distribution, cellular binding, and uptake o f AuNPs in K562 cells were

examined by laser scanning confocal microscopy. The cells was washed twice with IX
PBS after mixing with red fluorescence o f AuNPs (from Nanopartz, Inc.), followed by
fixation with 4% paraformaldehyde for 30 min. Nuclei were stained with 20 pM of
DAPI for 5 min at room temperature. Cells from each sample were then mounted on
cover glass slides. Images of phase contrast, red and blue fluorescence channels were
taken on a Zeiss 510 META Laser Scanning Confocal microscopy (Carl Zeiss
Microimaging, Inc., NY) and then the merged images were produced using the LSM
Imaging software. As AuNPs are well known to quench the fluorescent signal from
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proximal fluorescent probes, a sandwich design o f AuNPs (from Nanopartz, Inc., having
fluorophores separated from the gold surface with polymer spacer) was used to
circumvent this problem. Fluorophore labeled AuNPs with a CH 3 group terminated
surface (FNPs, 10 nm for AuNP core) were used to represent free, naked AuNPs used in
electroporation experiments. To visualize and track Tf-AuNPs, carboxylated AuNPs
(FNP-COOH) were utilized. FNP-COOH nanoparticles (1 mg/mL in PBS) were first
incubated with 1-Ethyl- 3-(3-dimethylaminopropyl) carbodiimide (20 mg/mL in PBS) for
15 min at room temperature. Transferrin solution (0.4 mg/mL in PBS) was then added
and incubated at room temperature for 24 hr to obtain FNPs with transferrin targeting
probes (Tf-FNPs). Tf-FNPs particles were then purified by repeated centrifugation and
resuspension in PBS for three times prior to the binding with transferrin receptors (TfR)
on K562 cell surface.
3 .2.11

Simulation on the Focusing Effect o f AuNPs
A commercial fmite-element methods (FEM) software, COMSOL (Mathworks,

Natick, MA), was used to calculate the electric field around the cell in the presence o f a
single AuNP. We considered an axially symmetric model with one AuNP (d = 20 nm)
embedded in the cell membrane (5 nm in thickness). A K562 cell (D = 15 m) was placed
at the center of the left side boundary (the symmetrical axis) in the computation domain
(60 m x 20 m). A polar angle (0) with respect to the electric field direction was defmed
and the AuNP was placed at the top of the cell where 6 = 180°. An electric field (E = 475
V/cm) was assigned across the top and bottom of the computation domain and the right
side boundary was set as the insulated wall. A three-layer cell model, divided as the
external medium, the cell membrane, and the cell cytoplasm, was set up here [191,249].
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The electric field distribution around the nanoparticle and the cell was calculated by
solving the Laplace equation using COMSOL:
V • ( ctW ) = 0

Eq. 3-1

where a is the electrical conductivity and V is the electrical potential. The electric field
strength was then determined by E = - W . In this three-layer cell model, the electrical
conductivity o f buffer, cytoplasm, membrane, and gold particle was set as 0.8,0.2, 5 x
10~7, and 4 * 107 S/m, respectively.
3.3
3.3.1

Results and Discussion

AuNPs Enhancement on the Transfection o f Mammalian Cells
We first electroporated K562 cells in both a commercial batch electroporation

(labeled as “BTX”) system and a home-made semi-continuous microchannel system
(labeled as “microchannel”), adopting the pulse conditions which were previously
optimized with gWiz™GFP plasmids alone: 125 V (625 V/cm), single 10 ms pulse for
the BTX system and 16 V (1067 V/cm), multiple 10 ms pulses for the microchannel
system. Transfection was successful in all four cases: BTX without AuNPs, microchannel
without AuNPs, BTX with AuNPs, and microchannel with AuNPs. Many cells in each
case expressed green fluorescence protein (GFP) 24 hr after electroporation (Figure
3-2A). More quantitative comparison was done by counting the percentage o f GFP
positive cells (Figure 3-2B) and cell viability (Figure 3-2C). Efficiency of pGFP
transfection from the microchannel was generally much better than that from BTX (BTX:
27.5 ± 1.9%, SFE: 51.6 ± 4.5%), which is consistent with our earlier observations [191,
247]. After adding AuNPs (5 nm at a concentration of 5X or 0.5 mg/ml), the transfection
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percentage was significantly increased to 50.8 ± 6.7% for BTX electroporator and to 61.1
± 4.8% for microchannel electroporator, respectively.

MicroChannel

BTX + AuNPs

MicroChannel + AuNPs

Figure 3-2: Gold nanoparticles enhancement on electroporation of K562 cells with a
commercial batch electroporation (labeled as “BTX”) system and a home-made semicontinuous microchannel system (labeled as “microchannel”). Panel (A) exhibits
fluorescence and phase contrast microscopic images o f pGFP plasmid transfection
through BTX, BTX with AuNPs, MicroChannel, and MicroChannel with AuNPs. The
left side shows expression o f GFP by the cells, and the right panel shows the cells
under phase contrast microscopy. Panels (B) and (C) are the quantitative results o f the
transfection efficiency (B) and die cell viability (C).The concentration of AuNPs use
here is 5X or 0.05 wt% (0.5 mg/mL). n = 6 and (***) represents p < 0.005.
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Some loss on the cell viability was observed (from 78.9 ± 2.9% to 57.4 ±5.1%
for BTX electroporator and from 69.9 ± 4.7% to 52.1 ± 2.3% for microchannel
electroporator), as shown in Figure 3-2C. This loss is not surprising considering the
focusing effect o f AuNPs could shift away the electric pulses from the desired strength.
As mentioned earlier, K562 cells in Figure 3-2 were excited at electroporation
conditions optimized in the absence of AuNPs. Considering the high conductivity o f
AuNPs, their addition greatly reduced the resistance contributed by the buffer solution
so that most electric voltage imposed between the two electrodes was allocated to the
cells. The actual pulse strength on the cell membrane was therefore mitigated to a
higher-than-optimal level, resulting in over perturbation to the treated cells. Such harsh
conditions increased the percentage o f irreversible breakdown o f the cell membrane,
making the loss of the cell viability inevitable. As this pulse strength focusing effect is
generated from the presence of free AuNPs in the electroporation buffer, the cell
transfection efficiency can be improved (when reversible breakdown still dominates) or
worsen (when irreversible breakdown becomes the dominant-cells might have probes
successfully delivered while not getting the subjected transgenes expressed prior to
lysis), depending on the concentration and size of the added AuNPs.
From the data shown in Figure 3-2C, the field focusing level for 5 nm AuNPs at
a concentration o f 5X (0.5 mg/ml) belonged to the first case (i.e., reversible breakdown
still dominated). The transfection of gWiz™GFP was improved while accompanied
with lower cell viability. Nevertheless, this experiment confirmed the electric field
focusing effect o f AuNPs to electroporation. (Note: the transfection percentage is
defined as the number o f transfected cell divided by the number of total living cells 24
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hr post transfection in each sample, and the cell viability is measured as the ratio o f the
living cells in each sample to that in the negative control samples.) These definitions
might differ from some others used in literature (divided by the number o f cells initially
used or cells surviving right after transfection) and emphasize the fate o f all survived
cells, though they sometimes show low values o f transfection (or the cell viability) for
their large number o f the total living cells.
Our FEM simulation confirmed the enhancement effects o f AuNPs to
electroporation. The electrical potential distribution is plotted by colorful contours while
the electric field lines through the buffer, the AuNP, and the cells are shown by blue
lines in Figure 3-3. Because o f the high conductivity, the electric field is clearly focused
near the AuNP. Such localized focusing effect could also help attract charged DNA
molecules from the surrounding area towards the focusing spot and enrich them there.
As transient pores will form later at the same location, we also compared the total
current passing through the pore with and without the AuNP present. It was found that
the current was enhanced 34% (from 1.77 nA to 2.38 nA) when a AuNP was around
(Figure 3-3C). This enhancement suggests that the charged DNA plasmids could
transport faster with AuNPs in close proximity and more o f them could be delivered into
the cells before the resealing of the cell membrane.
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Figure 3-3: Simulation of the electric field focusing effect of AuNPs in
electroporation. (A) The model and mesh setup for one AuNP embedded in the
membrane o f a K562 cell. (B) The calculated electric field lines around the AuNP. (C)
The electric field lines around a transient pore on the cell membrane in the presence of
one AuNP present.
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As the presence o f AuNPs greatly affects the pulse strength on treated cells, the
size and number o f AuNPs presented around each cell are critical to the electric pulse
strength focusing level and the resulting electroporation performance (the transfection
efficiency and cell viability). In the following sections, we evaluated the dependence of
the pulse strength focusing effect on the size and concentration o f AuNPs.
3.3.2

Dependence o f Electroporation Enhancement on the Concentration o f AuNPs
AuNPs o f various concentrations (0.1 X-10 X of the stock solution) were used to

evaluate the pulse strength focusing effect using the BTX electroporator. Similar to the
aforementioned results, when electroporating cells at their standard pulse conditions (625
V/cm, single 10 ms pulse), the transgene expression enhancement generally sacrificed
some o f the cell viability with the increase o f the AuNPs concentration (Figure 3-4A).
After adding 5 nm AuNPs at a concentration of 0.1 X -l X ( IX = 0.1 mg/mL AuNPs), the
cell viability retained at the same level (71.9 ± 51%-68.9 ± 29%) as in electroporation
with naked DNA. However, that value dropped gradually when more concentrated
AuNPs solutions (2.5 X-10 X) were used. Such cell viability loss endorsed the field
enhancing effect of free AuNPs mentioned earlier. Because the buffer resistance was
reduced when adding AuNPs, the local pulse strength on the cells was focused. When
starting from the standard pulse conditions, some treated cells were over-perturbed to
lethal levels. When increasing the concentration o f AuNPs, this pulse focusing effect got
continuously enhanced and more cells were over-polarized or died. As a consequence, the
cell viability dropped.
A threshold concentration o f AuNPs existed for this pulse-focusing effect: it did
not become obvious until the number of AuNPs reached a certain level (e.g., IX, 7.91 *
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1013 particles/ml for 5 nm AuNPs). Further increase in the pulse strength focusing effect
led to loss o f cell viability, but it was beneficial to the improvement o f the transfection
efficiency. For 5 nm AuNPs, the transfection efficiency increased from ~ 25% (bulk
electroporation with DNA only) to the maximum enhancement o f ~ 51% at the
concentration of 5 X (0.5 mg/mL or ~ 3.96 x 1014 5 nm AuNPs/ml) when increasing
AuNPs concentration and started decaying afterwards due to the significant loss on the
cell viability (Figure 3-4B).
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Figure 3-4: Dependence o f the pulse enhancement on the size and concentration o f
free AuNPs: panels ((A)-(B)) are the cell viability (A) and the transfection efficiency
(B) with an overall pulse strength o f 625 V/cm and panels ((C)-(D)) are the results with
an overall pulse strength of 475 V/cm (panel (C): the cell viability; panel (D): the
transfection efficiency). The blue and red dashes refer to die cell viability and the
transfection efficiency of electroporation with naked DNA at the optimal conditions
(675 V/cm, single pulse of 10ms), respectively. IX AuNPs refers to 0.01 wt% or 0.1
mg/mL gold content (n = 3).
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As the electric pulses were generally over-focused when concentrated AuNPs
were introduced at standard electroporation protocols, such enhancement might be more
beneficial when more benign conditions are used (at these conditions, transfection with
naked DNA alone is less effective as the consequence). At these conditions, the cell
viability is certainly high and the enhancement is mainly contributed to the improvement
on the transfection efficiency of molecular probes. During our investigation, to ensure the
local pulse strength was still effective for the majority of the cells, we lowered the overall
electric voltage (while keeping the pulse duration unchanged) to a minimum field
strength that was just enough to transfect a statistically meaningful number of cells with
DNA probes alone. For K562 cells, this minimum condition was 475 V/cm (95 V when
tested with 2 mm BTX cuvettes) with a 13.6 ± 15% transfection efficiency of naked DNA
using the BTX electroporator. As shown in Figure 3-4C, for all three sizes of AuNPs,
similar cell viability (±10%) was achieved within a broad concentration range o f AuNPs
(0.1 X-10 X). Different from the enhancement performance at standard conditions,
continuous increase on the transfection efficiency was achieved for all cases (Figure
3-4D). Such improvements were not only significant when compared to that using naked
DNA (i.e., ~ 14%) at the same pulse condition, but also much better than the best
performance the BTX electroporator could achieve with naked DNA (i.e., ~ 25%). This
additional gain on the transfection efficiency at benign electroporation conditions
confirmed from another viewpoint the focusing effect o f free AuNPs-low-voltage pulses
could be focused to high enough levels to provide the needed transmembrane field
strength for better transfection efficiency (40.0 ± 4.1% for 5 nm, 45.2 ± 4.0% for 10 nm,
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56.1 ± 3.3% for 20 nm). More important, such delivery enhancement was attained with
no or little sacrifice o f the cell viability for the application o f low-voltage pulses.
3.3.3

The Dependence of Electroporation Enhancement on the Size of AuNPs
Besides the concentration effect, the size of AuNPs also contributes to the

reduction o f the buffer resistance and the pulse strength focusing level on the cells.
Moreover, the size of AuNPs could affect the poration area on the cell membrane if
AuNPs are brought close enough. As shown in Figure 3-IB and Figure 3-3B, AuNPs
converge the electric field on their two poles and hang around the cells. The particles
work as many tiny virtual electrodes with focused pulses pointing towards the cell
membrane. This focusing could induce the polarization on the cell membrane within a
limited area (i.e., localized poration), which has been found to be beneficial for the
electroporation performance [185, 186, 191]. Therefore, the electroporation enhancement
with various sizes of AuNPs reflects a combination of the pulse strength focusing effect
and localized electroporation benefits. Three different sizes o f AuNPs (5 nm, 10 nm, and
20 nm) were tested here and their effects on the transfection efficiency and the cell
viability are included in Figure 3-4. Similar to AuNPs o f 5 nm, AuNPs of 10 nm and 20
nm exhibited similar concentration dependence on the transfection efficiency and the cell
viability. As the concentration of AuNPs in Figure 3-4 were calculated based on the
weight percentage o f added AuNPs, their buffer resistance reduction effect or the pulse
strength focusing level should be similar when the particle concentration is constant. In
other words, at the same concentration o f AuNPs, the enhancement difference for cases
in Figure 3-4 reflected mainly the contribution of various particle sizes to the localized
electroporation benefit.
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The enhancement difference on the transfection efficiency among various sizes of
AuNPs was marginal at low AuNP concentrations and became significant only when
more concentrated AuNPs were used. For 625 V/cm pulses, the effective AuNP
concentration started from 1 X AuNPs, and for 475 V/cm pulses, it started from 2.5 X,
due to their different pulse strength focusing levels and localized electroporation
situations. This effect o f concentration is reasonable as the pulse strength focusing effect
was weak at low AuNPs concentrations. Similarly, localized electroporation was very
limited at low AuNPs concentrations, as only a small portion o f the total free AuNPs
could aggregate around the cells. In excess of the threshold AuNPs concentration, their
contributions on the field focusing effect and localized poration became more
pronounced so that the benefit on the transfection efficiency improvement showed up.
The larger the size of AuNPs, the better transfection efficiency was achieved. Large
AuNPs of a relative lower concentration could also help gain better transfection
efficiency than small AuNPs at a higher concentration. For example, electroporation with
2.5 X and 5 X AuNPs o f 20 nm help achieve similar or even better pGFP transfection
than 5 X and 7.5 X AuNPs of 5 nm, respectively (Figure 3-4B and D). Among various
particle sizes, the cell viability difference at the same pulse strength focusing level (i.e.,
the same AuNPs concentration) was marginal in most cases. Therefore, these AuNPs (5
to 20 nm) are appropriate for the electroporation enhancement without extra addition to
the cell toxicity.
However, these results also suggested that, with free AuNPs (i.e., AuNPs that are
randomly dispersed in the electroporation buffer), the electroporation enhancement was
mainly decided by the pulse strength focusing effect or the concentration of AuNPs.
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Localized poration only became beneficial at high AuNPs concentration when sufficient
AuNPs were present around the cells during electroporation. However, this easily leads to
over-perturbation if added AuNPs are all free AuNPs. To further enhance the localized
poration effect, a sufficient number of AuNPs must be brought close to cells through
some pre-concentration approaches.
3.3.4

Enhancing Localized Electroporation with Transferrin-AuNPs
As many transferrin receptors (TfR) are available on the cell membrane o f K562

cells, AuNPs were conveniently brought to the cells by grafting transferrin (Tf)
molecules on their surface [250], This grafting was done with the help of the high affinity
o f sulfhydryl groups to the gold surface [251]. Specifically, sulfhydryl groups were
introduced to transferrin molecules by converting a small proportion o f their primary
amine groups to sulfhydryl groups with Traut’s reagent. The modified transferrin with
sulfhydryl groups were then incubated with free AuNPs to form transferrin AuNPs (TfAuNPs), as shown in Figure 3-5A. To evaluate how this transferrin-targeting mechanism
affected the localized electroporation, we incubated Tf-AuNPs o f 1 X with K562 cells for
various incubation times and compared their performance on transfection enhancement.
As shown in Figure 3-5B, the best improvement occurred in samples having 4-hr
incubation time and the transfection efficiency reached 41.7 ± 3.2% when compared to
that o f BTX with naked DNA (26.4 ± 1.9%) and BTX with free AuNPs (34.4 ± 2.9%).
Some 50% or less enhanced performance resulted from the gradual depletion of mobile
AuNPs in the electroporation buffer because of Tf-AuNPs grafting on the cell membrane.
As a consequence, though localized electroporation was improved, the pulse focusing
effect from free AuNPs diminished.
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Figure 3-5: Localized electroporation enhancement with Tf-AuNPs: (A) schematics of
grafting Tf-AuNPs as virtual electrodes on the cell membrane, (B) the localized
enhancement with Tf-AuNPs alone at various binding stages. The AuNPs used here are
20 nm with 1 X concentration (0.1 mg/mL). (n = 3)
To retain both the pulse strength focusing and localized electroporation
advantages, we added free AuNPs to Tf-AuNPs at various mixing ratios (0%, 25%,
50%, 75%, and 100% Tf-AuNPs). Based on other pioneering work on transferrin
targeting, it took about 4 hr incubation to accomplish complete affinity binding o f
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transferrin to the TfRs on the cells [248], Therefore, we first incubated K562 cells
with Tf-AuNPs for 4 hr and then added the needed quantity o f free AuNPs right
before electroporation. As shown in Figure 3-6A, such a combination showed better
enhancement o f the transfection efficiency under the standard electroporation
conditions with only 1 X total AuNPs (free AuNPs + Tf-AuNPs) while the actual
improvement varied with their mixing ratio: a sustained increase was seen on the
transfection efficiency when more Tf-AuNPs were added until reaching a 50%/50%
mixture o f free AuNPs and Tf-AuNPs (the transfection efficiency reached 58.2 ±
1.8%), followed by some declines. This combination provides ~ 2.5 folds increase on
the DNA transfection when compared to electroporation with naked DNA only.
Considering the low concentration o f AuNPs used here (only 1 X), the electroporation
enhancement with a combination of free AuNPs and Tf-AuNPs seems more effective
than that using free AuNPs or Tf-AuNPs alone.
The best enhancement came from an appropriate balance on the pulse strength
focusing and localized electroporation advantages AuNPs offered. It is worth
mentioning that such a transfection efficiency improvement was achieved without
sacrificing much o f the cell viability (Figure 3-6A). At more benign conditions (475
V/cm), the enhancement was not very obvious, consistent with the free AuNPs
enhancement result at low concentrations (0.1 X -l X). This insufficient pulse
focusing level cannot provide the desired transmembrane potential to polarize the
majority o f the cells. When more AuNPs were introduced (e.g., 5 X for the total
AuNPs concentration), the enhancement on the transfection efficiency became
significant for pulses o f both 625 V/cm and 475 V/cm and die equivalent mixture of
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free AuNPs and Tf-AuNPs still offered the best transfection efficiency (Figure 3-6B).
However, because of the over-focusing effect, obvious loss o f the cell viability was
found for the case with the pulse strength o f 625 V/cm, consistent with our earlier
observations.
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Figure 3-6: The combined enhancement o f the pulse strength focusing and
localized electroporation effects using a mixture o f free AuNPs and Tf-AuNPs o f
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3).
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3.3.5

AuNP Imaging and Tracking In Vitro
We tracked the cellular uptake of AuNPs before and after electroporation for both

free, naked AuNPs and Tf-AuNPs using confocal microscope and the results were shown
in Figure 3-7. As free AuNPs were mixed with cells right before electroporation, the
short contact time did not provide enough time to allow endocytosis-based uptake of
AuNPs and no obvious fluorescently labeled AuNPs (FNPs) were observed (Figure
3-7A). After electroporation, many FNPs were clearly found in the cell cytoplasm (Figure
3-7B), indicating that AuNPs transported into the cells after electroporation. As all
samples were fixed shortly after electroporation, we believe the majority o f FNPs were
taken through the transient openings on the cell membrane, not the endocytosis process.
As mentioned in our FEM simulation, AuNPs around transient pores could enhance the
cellular uptake of DNA plasmids because of the increase o f electrical current (see Section
AuNPs Enhancement on the Transfection o f Mammalian Cells). Figure 3-7 C and D
showed the distributions of Tf-FNPs before and after electroporation (Note: Tf-FNPs
alone, not a mixture with free FNPs were used here). The accumulation of Tf-FNPs on
the cell membrane was clearly found in the samples without electroporation treatment
(Figure 3-7C), confirming the formation of ligand-receptor bonds after incubation. After
electroporation, FNPs were also found in the cell cytoplasm (Figure 3-7D), consistent
with what was exhibited in free FNPs electroporation. However, unlike in the free FNPs
electroporation sample, many Tf-FNPs were also found on the cell membrane or regions
nearby, suggesting that at least some Tf-AuNPs conjugates and the coupling o f Tf-TfR
could survive the electroporation process.
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Figure 3-7: The confocal microscope images of the cellular uptake of AuNPs before
and after electroporation: ((A)-(B)) for free FNPs and ((C)-(D)) for Tf-FNPs. Images in
panels (A) and (C) were taken before electroporation and panel (B) and (D) were after
electroporation. FNPs of 10 X or 0.1 wt% (1.0 mg/mL) were used in all samples and
Tf-FNPs were incubated with the cells for 4 hr.
3.3.6

Enhancement Performance o f AuNPs in Fibroblast
Leukemia cells K562 was selected in the aforementioned experiments on the basis

that it is hard to transfect the suspension cell line. At the same time, we also tested with
an adherent cell line - NIH 3T3 fibroblast.
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Firstly, AuNPs of various concentrations (0.1 X - 2 X of the stock solution) were
used to evaluate the pulse strength focusing effect with NIH 3T3 cells. Similar to the
aforementioned results with K562, the transgene expression enhancement generally
sacrificed some o f the cell viability with the increase of the AuNPs concentration when
electroporating cells at their standard pulse conditions (625 V/cm, single 10 ms pulse), as
shown in Figure 3-8B. The cell viability tended to drop at higher AuNP concentrations
(starting from 1 X). Such cell viability loss endorsed the field enhancing effect of free
AuNPs mentioned earlier, that is, some treated cells were over-perturbed to lethal levels.
The transfection efficiency increased from ~ 25% (bulk electroporation with DNA only)
to the maximum enhancement of ~ 45% at the concentration o f 2 X (0.2 mg/mL or ~
1.58 x 1014 5 nm AuNPs/ml).
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4X AuNPs

X AuNPs

(B)
100
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Transfection Efficiency
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DNA only

0.4X
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Concentration o f AuNPs

Figure 3-8: The pulse enhancement of free AuNPs (5 nm) on NIH 3T3 cells: panels
(A) present phase contrast and fluorescence microscopic images of cells after BTX
electroporation with naked DNA alone, with 0.4 X, 1 X, and 2 X AuNPs, respectively.
Panel (B) is the summary o f the quantified cell viability by MTS assay and the
transfection efficiency by flow cytometry. A single pulse with 10 ms pulse duration
and 625 V/cm overall pulse strength was imposed for all samples and IX AuNPs refers
to 0.01 wt% or 0.1 mg/mL gold content, n = 3 and (***) represents p < 0.005.
Secondly, two different sizes of AuNPs (5 nm and 20 nm) were tested with
both commercial batch electroporation (BTX) and home-made semi-continuous
microchannel system (SFE); their effects on the transfection efficiency and the cell
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viability are included in Figure 3-9. According to our previous observation, the
enhancement difference on the transfection efficiency among various sizes o f AuNPs
was marginal at low AuNPs concentrations and became significant only when
concentrated AuNPs were used. Moreover, the larger the size of AuNPs, the better
transfection efficiency was achieved. Here, we chose to test with 1 X, 5 X 5 nm and 5
X 20 nm AuNPs. The transfection efficiency grew with the increase o f the particle
size and concentration, while cell viability was reasonably scarified. Similar trends on
the transfection efficiency and cell viability were found, consistent with those o f K562
cells. This confirms the broad effectiveness of the enhancement roles AuNPs play in
electroporation.
(A)
100;

(B )

EP+AuNPs
20nm, 5X

EP+AuNPs
5nm, 5X

EP+AuNPs
20nm, 5X

5nm, 5X

EP+AuNPs
5nm, IX

EP alone

EP alone
5nm, IX

Figure 3-9: The pulse enhancement o f AuNPs for electroporation of NIH 3T3 cells
with a commercial batch electroporation (labeled as “BTX”) system and a home-made
semi-continuous microchannel system (labeled as “SFE”). Panels (A) and (B) are the
quantitative results of the cell viability and transfection efficiency, respectively (n = 3).
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3.4

Conclusions

AuNPs were used to enhance in vitro delivery o f DNA probes for both batch-type
and flow-through electroporation systems. Highly conductive free AuNPs were added to
the electroporation buffer to reduce the solution resistance so that the pulse strength on
the cells could be enhanced. Tf-AuNPs were brought to K562 cells through affinity
binding with TfR receptors on the cell membrane, serving as many virtual
microelectrodes to polarize cells locally from various sites, each affecting only a limited
area. In this way, electroporation was enhanced with better transfection efficiency and the
same or higher cell viability. With DNA plasmids carrying a gWiz™GFP reporter gene,
we confirmed the pulse strength focusing effect after adding free AuNPs in the
electroporation buffer and investigated its dependence on the particle size, concentration,
and electroporation conditions. The enhancement difference among various sizes was not
significant until higher concentrations were used, and the best transfection was achieved
with 20 nm nanoparticles. At 125 V, a threshold concentration o f AuNPs existed for
pulse-focusing effect and the transfection efficiency increased to maximum at a
concentration o f 5 X. At 95 V, transfection efficiency was continuously increasing with
concentration. We also observed the contributions o f localized electroporation with TfAuNPs.
An equivalent mixture o f free AuNPs and Tf-AuNPs was found to provide the
best enhancement performance while the optimal concentration o f AuNPs was decided
by the original pulse conditions. This study offers a new approach to improve the
delivery efficiency of nucleic acids or anticancer drugs through the combination of
nanoparticles and electroporation technologies. AuNPs were adopted here for their low
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cost and easy accessibility while other forms of gold nanostructures, such as nanorod,
nanoshell, or nanowires, in principle, could be used for similar purposes. As these gold
nanomaterials have been widely explored in sensing, imaging, diagnosis, and therapeutic
applications, our approach demonstrates a new function of these nanomaterials and/or
broadens their potentials for multiple-function applications in drug discovery and clinical
practice.

CHAPTER 4
GOLD NANOPARTICLES ELECTROPORATION ENHANCED
POLYPLEX DELIVERY TO MAMMALIAN CELLS

4.1

Introduction

Polyplex serves as the favorable alternative to their virus-mediated counterparts
and have been successfully tested for both in vitro and in vivo delivery o f plasmids,
oligonucleotides, ribozyme, and small interfering RNAs [3-15]. However, many of these
systems still suffer insufficient delivery efficiency and cell viability, which often ties with
their poor nanoparticle quality, slow and inefficient cellular uptake with endosome
escape, and serious cytotoxicity from free cationic molecules after the unpacking of
lipoplex or polyplex. As captured cationic molecules are much less toxic than their free
counterparts, nanoparticles have been introduced to help fix cationic polymer [74],
AuNPs are favored in these applications for their good biocompatibility and multiple
functionalities (i.e., targeting, therapeutic, and imaging) [74, 143, 162-165, 252],
However, issues like ineffective cellular internalization remain.
Herein we introduce the use o f electroporation to bypass the slow and inefficient
endocytosis process by directly delivering therapeutic probes into cell cytosol. A simple
combination of lipoplex nanoparticles and electroporation has been explored early in the
delivery o f oligonucleotides in the format of lipoplex [247, 253]. However, negative
impacts on both the delivery efficiency and the cell viability were found [253], We
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believe that the destroyed complex structure during electroporation released a large
number o f free cationic molecules, which significantly lower the overall cell viability. To
avoid a similar situation, we first immobilized the cationic polymer on AuNPs and then
allowed conjugation with negatively charged therapeutic probes to form AuNPs-polyplex
complex. In addition to the help on retaining cationic polymer on the surface, the
presence o f AuNPs also enhances the electroporation performance with focused electric
pulses and localized poration [254], which was proven beneficial for not only the
recovery of treated cells to gain high cell viability, but also the uptake of probes from
multiple sites to facilitate the cytosolic delivery. Specifically, cationic polymer,
polyethylenimine (PEI), was immobilized on AuNPs by electrostatic interactions (Figure
4-1). DNA plasmids were then conjugated with PEI molecules to form AuNPs-polyplex.
The complex nanoparticles were then mixed with cells for electroporation. The delivery
enhancement was evaluated by the cell viability and the transfection efficiency.

150mMNaCl

AuXP plyplex
Poiyathytwwnine (PEI)

*

* a

Citric aad group
DNA

Figure 4-1: Schematic illustration on the procedure o f AuNPs-polyplex synthesis and
delivery.
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4.2
4.2.1

Materials and Methods

Materials and Reagents
Branched PEI (MW = 25 kDa), AuNPs o f 5 - 40 nm were obtained from Sigma-

Aldrich. The concentration of 1 X AuNPs refers to the stock solution, which has 0.01
wt% of Au (0.1 mg/mL) while the number o f particles varies with the size of AuNPs.
Other concentrations of AuNPs were prepared by either concentrating or diluting from
the stock solution. DNA plasmids with gWiz™GFP was purchased from Aldevron
(Fargo, ND). All other chemicals were purchased from Sigma-Aldrich and the cell
culture reagents were purchased from Life Technologies (Carlsbad, CA) unless specified.
4.2.2

Preparation of AuNPs-polvolex
To prepare AuNPs/PEI polyplex, 500 pL 0.5 mg/mL PEI (pH 7.0) was added to

500 pL 0.01 wt% o f AuNPs. The original citric acid terminated surface o f AuNPs
facilitates the deposition of PEI molecules through electrostatic interactions. The
incubation was performed at room temperature for 20 min and the extra PEI was removed
by centrifuging at 15,000 x g for 10 min. The PEI-coated AuNPs were resuspended in a
desirable amount of PBS (pH 7.0) and 5 pL o f nucleic acid solution (with a concentration
o f 5 mg/mL) was added to AuNPs/PEI o f varying concentrations. The resulting mixture
was mixed by pipetting and further incubated at room temperature for 20 min.
4.2.3

NIH 3T3 and K562 Cell Culture
NIH 3T3 cells were obtained from American Type Cell Culture (ATCC,

Manassas, VA). They were grown and maintained in high-glucose DMEM supplemented
with 10% newborn calf serum, 1% penicillin and streptomycin, 1% L-glutamine, and 1%
sodium pyruvate. For subculture, culture medium was removed and discarded first. The

cell layer was briefly rinsed with DPBS to remove the serum which contains trypsin
inhibitor. Then 1-2 mL trypsin-EDTA was added for a 100 cm2 Petri dish. Cell culture
was then observed under an inverted microscope until the cell layer was dispersed
(usually 5-15 min); 8 to 9 mL of complete growth medium was added and cells were
aspirated by gently pipetting. Appropriate aliquot of the cell suspension was transferred
to a new culture dish with an addition o f more growth medium to make a total volume of
10 mL for 100 cm2 surface. K562 lymphoblast cells were also obtained from American
Type Cell Culture (ATCC, Manassas, VA). K562 cells were cultured and maintained in
R P M I1640 media supplemented with 10% heat-inactivated fetal bovine serum (FBS),
100 U/mL penicillin, 100 g/mL streptomycin, and L-glutamine. For subculture, a desired
amount of K562 cell suspension was transferred to a new Petri dish with the addition of
an appropriate amount of fresh culture medium. All cultures were maintained at 37 °C
with 5% CO2 and 100% relative humidity.
4.2.4

Electroporation Setup and Procedure
NIH 3T3 or K562 cells were counted with hemocytometer to determine cell

density, centrifuged at 200 x g for 5 min and then resuspended in fresh GIBCO OPTIM EM I (a serum free medium) at the desired densities o f 0.5 * 106 - 0.5 * 107 cells/mL.
Cell suspensions were then mixed with AuNP-polyplexes of various concentrations and
sizes while the amount of DNA plasmids was fixed at 25 pg/sample. Electroporation was
done with a commercial instrument (ECM 830, Harvard Apparatus) in cuvettes with a 2mm gap, each containing a 100 pL sample solution. The standard electroporation
condition (single 10 ms pulses of 125 V / 2 mm cuvette) was applied with a single
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unipolar pulse. After electroporation, the samples were transferred to 6-well cell culture
plates, incubated in a fresh medium for another 24 h, and then harvested for analysis.
4.2.5

Determination o f AuNPs-polvplex Delivery Efficiency
The transfection efficiency of gWiz™GFP plasmids was evaluated both

qualitatively by visualizing the number o f cells with green fluorescence within a
representative area selected from the entire culture surface under an inverted fluorescence
microscope (Olympus, Japan) and quantitatively by counting cells using a four-color flow
cytometry system (FACS Calibur, BD Biosciences, CA) 24-h post transfection. Briefly,
an amount of 1.5 * 106 cells/mL was collected and the percentage o f GFP-positive cells
was calculated quantitatively via the flow cytometer. The unstained samples were ran
first to adjust the voltage setting and compensation o f the flow cytometer. Then the tested
samples were processed by CellQuest. At least 10,000 events were collected for each
sample.
4.2.6

Measurements of Cell Viability
The cell viability was evaluated by an MTS cell proliferation assay (Promega,

Madison, WI). Briefly, the cells in 100 pL/well o f medium were transferred to a 96-well
plate and incubated. Twenty microliters o f CellTiter 96 AQueous One solution (Promega,
Madison, WI) was added to each well and the cells were incubated at 37 °C for another 1
h. Absorbance was measured at 492 nm on an automated plate reader (Elx 800, Biotek,
VT). Normally, grown cell samples were used as negative control whose viability was set
to 100%. Data points were represented as the mean ±SD of triplicates, unless otherwise
indicated.
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4.2.7

Cellular Uptake o f AuNPs-polvplex Nanoparticles
The distribution of AuNPs-polyplex in 3T3 cells was examined using an inverted

fluorescent microscope. As AuNPs are well known to quench the fluorescent signal from
the proximal fluroprobes, a sandwich design of fluorophore-labeled AuNPs (FNP from
Nanopartz, having Alexa Fluor 546) with fluorophores separated from the gold surface
by polymer spacers were used to circumvent this problem. Plasmids were stained with
YOYO-1 iodide (Life Technology) with a ratio o f 100 bp/dye. The mixture of cells with
nucleic acids, AuNPs, or AuNPs-polyplex were washed twice with 1x PBS (pH 7.0),
followed by fixation with 4% paraformaldehyde for 30 min. Nuclei were stained with 20
pM of 4’, 6-diamidino-2-phenylindole (DAPI) for 10 min at room temperature. Cells
from each sample were then mounted on cover glass slides. Images o f the phase contrast,
green (nucleic acids), red (AuNPs), and blue (nuclei) fluorescence channels were taken
on an Olympus

1x51

inverted microscope (Olympus) with a 100

x

objectives.

Note that in our nomenclature, symbols such as “A/B” or “A - B” means
materials A and B are conjugated together through electrostatic interactions after
incubation; “A + B” means A and B are simply mixed without incubation before further
treatment.
4.3
4.3.1

Results and Discussions

AuNPs-polvplex Size and Size Distribution
Current polyplex delivery vehicles have not yet shown competitive delivery

advantages over natural virus-based counterparts. This result is at least partially attributed
to their heterogeneous assembly conditions and poor synthetic quality o f nanoparticles
(i.e., relatively large variations in size, structure, and component quantity). As in our
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AuNPs-polyplex synthesis, cationic polymer molecules (i.e., PEI) were first immobilized
on the surface o f AuNPs; their amount in individual AuNPs-polyplex should be more
uniform than those synthesized through dynamic complexation o f freely charged agents.
This further determines the total dosage o f genetic probes, which are condensed on
AuNPs-polyplex later on. Therefore, the introduction o f AuNPs in the polyplex not only
helps fix free or dissociated polycations on a solid surface, but also provides better
management on molecule assembly and multiple-agent packaging. As a consequence,
nanoparticles o f better quality are produced.
As shown in atomic force microscopy (AFM) images in Figure 4-2, more
homogeneous morphology was found for AuNPs-polyplex than polyplex synthesized via
vortex mixing (Figure 4-2E) [4]. Their size was also much smaller and more uniform,
which was further confirmed with quantitative measurements using dynamic light
scattering (Figure 4-2F). Except for AuNPs-polyplex synthesized from 5 ran AuNPs, the
average size o f AuNPs-polyplex with various original sizes lies between 100 and 200 nm,
an appropriate size range of nanoparticles for efficient cellular uptake. As the size of
DNA plasmids used in this study is much bigger than that o f AuNPs, each DNA molecule
is suspected to interact with multiple AuNPs-PEl nanoparticles simultaneously (Figure
4-3). Therefore, clusters (or aggregates from conjugation networking) of AuNPs-PEIDNA, instead o f many individual AuNPs-polyplex nanoparticles with the assembly
structure schematically shown in Figure 4-1, are more likely to form. With smaller size
and higher mobility, AuNPs o f 5 nm allow easier occurrence of such conjugation
networking than other AuNPs with larger original size. As a result, such stable clusters
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might become the dominated population when small AuNPs are used in AuNPs-polyplex
synthesis.
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Figure 4-2: The AFM images o f AuNPs-polyplex morphology with the original size of
AuNPs o f (A) 5 nm, (B) 10 nm, (C) 30 nm, and (D) 40 nm. Panel (E) is the traditional
polyplex synthesized through the vortex mixing approach [4]. Panel (F) is the
quantitative dynamic light scattering (DSL) particle size measurement.
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Figure 4-3: Schematic o f AuNPs-polyplex formation involving conjugation
networking o f multiple AuNPs with DNA probes.
4.3.2

Cellular Uptake of AuNPs-polvplex via Electroporation
To verify that PEI molecules remain on AuNPs during electroporation,

fluorescence probes were tagged to track the locations and fate o f AuNPs-polyplex
during the cellular uptake. As AuNPs quench fluorescent signal from proximal
fluroprobes, FNP with polymer spacer separating fluorophores from the gold surface was
utilized. These nanoparticles are also carboxylated to match similar interaction capacity
as those with citric acid terminated surface. After conjugating with PEI molecules,
fluoroprobes are pushed back to the gold surface, and therefore, the fluorescent signal of

61
FNP is quenched again unless most immobilized PEI molecules are gone. When DNA
plasmids are condensed on FNP, the PEI layer underneath serves as the new thick spacer
so that the YOYO-1 labeled DNA probes become visible and are used to track the uptake
of AuNPs-polyplex.
Compared to the untreated sample (Figure 4-4A), samples o f simply mixing cells
with YOYO-1 labeled DNA plasmids (Figure 4-4B) or FNP (Figure 4-4C) have weak
fluorescent spots visible. This weakness is attributed to their tiny particle size and limited
fluorescent signal when staying as individual nanoparticles. After the nanoparticles were
capped with a layer o f PEI, even such weak fluorescent signals disappeared (Figure
4-4D), which confirmed that the original fluorophores were pushed back close to the gold
surface. As the PEI layer serves as the new spacer layer, the condensed DNA plasmids
labeled with YOYO-1 exhibited a similar fluorescent signal as free DNA plasmids
(showing weak green fluorescence spots in Figure 4-4E), indicating that the location o f
AuNPs-polyplex was mainly outside the cells. After electroporation, stronger fluorescent
signals were generally seen in electroporated cells with naked plasmids and FNP as
nanoparticles accumulated in the cells (Figure 4-4 F and G). No fluorescent signal was
observed for the sample using PEI-coated FNP (Figure 4-4H), though similar
accumulation of AuNPs-PEI nanoparticles was clearly observed in the phase contrast
image. This suggests that the electric pulses did not break the interactions between
AuNPs and PEI molecules. For YOYO-1 labeled AuNPs-PEI-DNA polyplex, a strong
green fluorescent signal was shown inside the cells (Figure 4-41). As the samples were
fixed immediately after electroporation, this fluorescence clearly indicates the similar
quick and direct cytosolic delivery of plasmids by electroporation.
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Figure 4-4: Phase contrast and fluorescence microscopic images of distribution and fate
o f AuNPs-polyplex when mixing with NIH 3T3 cells (A-E) and immediately after
electroporation (F-I): (A) untreated samples (negative control); (B) mixture o f cells and
naked DNA plasmids (green); (C) mixture o f cells and FNP (red); (D) mixture of cells
with FNP/PEI nanoparticles; (E) mixture o f cells with FNP/PEI/DNA; (F) electroporation
with DNA alone (green); (G) electroporation with FNP (red); (H) electroporation with
FNP/PEI; and (I) electroporation with FNP/PEI/DNA. TTie 100 X objective was used.
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4.3.3

Plasmid DNA Delivery in NIH 3T3 Cells bv AuNPs-polyplex
We further explored the delivery of DNA plasmids from AuNPs-polyplex by

electroporation. The electroporation was done with NIH3T3 cells with a BTX system
using gWiz™GFP plasmids and the following pulse scheme was applied: 125 V (625
V/cm), single 10 ms pulse. Successful transfection was observed 24 h after
electroporation in all four cases: electroporation with DNA alone (no AuNPs), with
AuNPs + DNA, with polyplex (no AuNPs), and with AuNPs-polyplex, as shown in
Figure 4-5. However, a simple combination of electroporation and polyplex showed a
significant negative impact on both the delivery efficiency and cell viability (Figure
4-5B), which is consistent with an earlier observation for lipoplex delivery using a similar
approach [253], The poor quality and loose structure of the polyplex might have been
destroyed to release a large number of free cationic PEI molecules. These free positively
charged macromolecules, together with additional harsh electric pulses, further lowered
the overall cell viability and transfection when compared to the electroporation o f naked
plasmids (Figure 4-5A). Electroporation of polyplex and AuNPs-polyplex with various
N/P ratios was conducted as additional proof. As shown in Figure 4-6, with the increase
o f the N/P ratio, which was an increase in the amount o f PEI, more dead cells were
observed for polyplex electroporation as well as extremely poor transfection (cells had
probably died before gene expression). However, AuNPs-polyplex electroporation with
various N/P ratios showed an insignificant difference in cell viability while successful
transfection was observed in all these groups. Electroporation delivery of the plasmids
together with AuNPs and AuNPs-polyplex showed better GFP expression (Figure 4-5 C
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and D), which confirmed again our early observation that the enhancement of AuNPs to
electroporation performance [254],

(A) Naked DNA electroporation

(B) Polyplex electroporation

(C) AuNPs electroporation

(D) AuNPs-Polyplex electroporation

Figure 4-5: Fluorescence and phase contrast microscopic images o f pGFP plasmid
transfection to NEH 3T3 cells by electroporation.

(A) Polyplex electroporation
N/P-1.1

(B) AuNPs-Polyplex electroporation
N/P-1.1

N/P-3.3

N/P-6.7

Figure 4-6: Fluorescence and phase contrast microscopic images o f pGFP plasmid
transfection to NIH 3T3 cells by polyplex and AuNPs-polyplex electroporation.
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More quantitative comparison was done by counting the percentage of GFPpositive cells using flow cytometry (Figure 4-7). Efficiency o f pGFP transfection
from AuNPs-polyplex ( using 5 nm AuNPs at a concentration of 1x or 0.1 mg/mL)
was about one and a half fold of that using naked plasmids and a simple mixture o f
DNA and AuNPs (DNA alone: 34.8 ± 2.0%; 5 nm AuNPs and DNA: 44.4%; 5 nm
AuNPs-polyplex: 53 .4%). When large sized AuNPs (10-40 nm for their original size)
were used, the transfection efficiency was further enhanced to about two-fold o f that
using naked DNA alone. For comparison, the GFP transfection using electroporation
with polyplex was only about one third o f that standard electroporation. Greater loss
of the cell viability (i.e., 10%) was observed in AuNPs-polyplex electroporation
samples than that using naked DNA. However, it is worth the sacrifice of using
electroporation to bypass the endocytosis delivery route with direct cytosol delivery
and 1 .5 -2 folds increase in the transfection efficiency. When comparing cell viability
o f 40% (i.e., less than half of the standard electroporation of naked DNA, 90%) with
polyplex in electroporation, our approach of introducing AuNPs to fix free or
dissociated PEI is effective. This observation was also endorsed with further complex
cytotoxicity analysis without electroporation (Figure 4-8).
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Figure 4-7: Quantitative measurement of electroporation enhanced AuNPs-polyplex
delivery performance on 3T3 cells: (A) the flow cytometry results on transfection
efficiency and (B) the cell viability via MTS assay. As comparison, results from
electroporation with DNA alone, polyplex, and samples o f a simple mixing o f AuNPs
and DNA are also shown. The error bars correspond to triplicate experiments made
with independently produced batches, n = 3 and (***) represents p < 0.001.
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Figure 4-8: The viability of NIH 3T3 cells when incubated with AuNP-polyplex and
polyplex determined by MTS assay. PEI is the cationic polymer used here and the
incubation was performed at various N/P ratios. The cell viability o f commercial bulk
electroporation (labeled as “BTX”) is also provided for comparison purpose (n = 3).
In this delivery improvement, the AuNPs core helps enhance the electroporation’s
performance from two different aspects [254]: (i) reducing the resistance o f the
electroporation buffer solution so that the local pulse strength on the cells is enhanced;
(ii) serving as virtual microelectrodes to locally porate cells with a limited area from
many different sites. Because of their high conductivity (4.5 * 106 S/m), AuNPs
dispersed in the buffer and cytoplasm (the conductivity is 0.3 -1.5 S/m) help greatly
reduce the potential drop so that the majority o f the electric voltage is imposed on the cell
membrane indeed. The cell membrane disruption could therefore be done more
effectively without altering the cell physiological conditions (i.e., salt concentration) or
losing cell viability. When the electric field converges in the vicinity o f AuNPs, they
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work like many virtual nanoelectrodes to cause localized poration. Different from the
traditional bulk electroporation with two large breakdown locations, multiple small
poration sites are formed after adding AuNPs that benefit not only the recovery o f the cell
membrane, but also the cytosolic delivery o f plasmids from multiple sites.
The contribution of AuNPs-polyplex to the transfection improvement of DNA
plasmids is also multifactorial: (i) they help fix PEI on the surface of AuNPs to
significantly reduce the toxicity caused by the presence o f free and/or dissociated cationic
polymer molecules in the polyplex (Figure 4-8), (ii) they effectively produce polyplex
nanoparticles with smaller average size than the naked DNA plasmids and narrower size
distribution when compared to that from the vortex mixing synthesis (Figure 4-2F), (iii)
the PEI molecules in AuNPs-polyplex help protect DNA plasmids and condense them
near the vicinity o f the cell membrane to promote the cytosolic delivery and also later for
nuclear transport. These effects offer AuNP-polyplexes advantages over the use o f the
mixture of AuNP and naked DNA in electroporation (Figure 4-7) as well as many
traditional transfection approaches (Figure 4-9) on the transfection efficiency and cell
viability. The slight loss on cell viability (Figure 4-7B) probably results from the
presence of some free PEI molecules to the electroporated cells.
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Figure 4-9: Comparison o f AuNPs-polyplex electroporation was compared to
traditional transfection approaches PEI/DNA polyplex at two different N/P ratios (6.6
and 10) and lipo2000 at two different dosages (“optimal” refers to the protocol
recommended dosage; and “scaled up” refers to the case with increased lipo2000 dose
to match the actual DNA amount use in electroporation) (n = 3).

4.4

Conclusions

In summary, we immobilized the polyplex on AuNPs and delivered them into the
cells through electroporation. Conjugating with AuNPs helps minimize the cytotoxicity
concerns from polyplex after cytoplasmic release while still retaining good probe
protection. It also avoids poor nanoparticle quality existing in traditional polyplex
synthesis, namely large size and broad size variations, by managing molecule interactions
and assembly on the surface o f AuNPs. Combined with electroporation, conjugated
polyplex (AuNPs-Polyplex) showed quick delivery and significant enhancement o f the
transfection efficiency with no obvious increase o f toxicity. Such a combination of
physical and chemical delivery concept may stimulate further exploration in the delivery
o f various therapeutic materials for both in vitro and in vivo applications.
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The choice o f AuNPs in the enhancement of polyplex delivery lies on their high
conductivity and excellent biocompatibility. Their other potential advantages, such as
sensing signal enhancement via localized surface plasmon resonance or surface-enhanced
Raman spectrum, have not yet been investigated with this gene delivery approach. Our
approach however has a promising potential to integrate both diagnostic and therapeutic
functions in one nanosystem (namely nanotheranostics) to accomplish both noninvasively
tracking the targeting therapeutic probes and measuring their delivery performance
simultaneously. This integration will surely help increase our understanding on the
regulation mechanism o f many therapeutic probes and quickly establish appropriate
strategies to improve their delivery or treatment performance. Other forms o f gold
nanostructures, such as nanorod, nanoshell, or nanowires, in principle, could also be used
for the similar purposes. Their success will accelerate and broaden the applications of
these nanomaterials in drug discovery, cancer diagnosis, and treatment, and/or
regenerative medicine where quick and precise diagnosis and therapeutics is urgently
needed.

CHAPTER 5
GOLD NANOPARTICLE ENHANCED SMALL NUCLEOTIDE
MOLECULE DELIVERY BY ELECTROPORATION TO
MAMMALIAN CELLS

5.1

Introduction

RNA interference is an endogenous process where small interfering RNA
(siRNA) molecules regulate gene expression by silencing mRNA targets. Since the first
report from Fire’s group that siRNA was responsible for gene silencing in C. elegans,
RNA interference has been attracting attention in mammalian cell processes and as a
treatment for diseases [255-263], Various carriers, such as cationic polymers, lipids and
nanoscale materials, have been investigated for siRNA delivery [74,264-269]. However,
the safety and delivery efficiency still remain as a challenge for clinical application o f
siRNA [270-273].
MicroRNAs (miRNAs) are small (contains approximately 22 nucleotides)
endogenous non-coding RNAs that function in RNA silencing at the posttranscriptional
level through base pairing with mRNA molecules [274,275]. They regulate a broad
network o f genes since this base pairing is not necessarily perfect. It has been recently
demonstrated that down regulation of miR-29 family members in various cancer cells
may contribute to the abnormal cell proliferation, apoptosis and migration [276-285].
Therefore, the miR-29 family has become a research focus o f miRNA-based therapy and
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attracted much attention as a new strategy in cancer treatment. However, delivery o f
miRNAs encountered critical hurdles including, but not limited to, poor stability, rapid
blood clearance, and insufficient cellular uptake.
Polyethylenimine (PEI) has been used as a non-viral carrier for its ability to
electrostatically interact with nucleic acids and protect them from intracellular enzymes.
While the delivery o f plasmids with PEI has been proven to be efficient, siRNA
transfection with PEI has been shown to be less satisfying because of die stiffer nature of
RNA molecules compared to DNA [4,286-289]. Moreover, the toxicity of PEI is
associated with its positive charges, enabling it to interact strongly with cell membranes
and result in damage. Therefore, modification o f PEI to reduce the positive charge could
be an option to improve its delivery performance.
In our study, we used electroporation to bypass the slow and inefficient
endocytosis process by directly delivering therapeutic probes into the cell cytosol. As the
followup o f our previous study, we applied AuNP to enhance electroporation
performance - AuNPs were coated with cationic polymer and further conjugated with
negatively charged RNA molecules to form AuNPs-polyplex. The presence of AuNPs
helped to focus electric pulses and localize poration, which was proven beneficial for not
only the recovery of electroporated cells, but also the uptake of probes from multiple sites
to facilitate the cytosolic delivery. The AuNPs enhanced RNA delivery was evaluated by
the cell viability and the down regulation of the targeted genes.
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5.2
5.2.1

Materials and Methods

Materials and Reagents
Branched PEI (MW = 25 kDa), AuNPs were obtained from Sigma-Aldrich (St.

Louis, MO). The concentration of 1 X AuNPs refers to the stock solution, which has 0.01
wt% of Au (0.1 mg/mL) while the actual particle number varies with the size o f AuNPs.
DNA plasmids with gWiz™GFP and gWiz™Luc reporter genes were purchased from
Aldevron (Fargo, ND). siRNA used for silencing GFP (expressed by pMaxGFP
purchased from Lonza) and luciferase genes were synthesized by Thermo Scientific
(Pittsburgh, PA) and the sequences were as follows: siRNA for GFP silence, sense strand,
5-CGCAUGACCAACAAGAUGAUU-3; antisense strand, 5UCAUCUUGUUGGUCAUGCGGC-3; luciferase GL3 duplex (Luc-siRNA); sense
strand, 5-CTJUACGCUGAGUACUUCGA-3; antisense strand, 5UCGAAGUACUCAGCGUAAG-3. miRIDIAN microRNA human hsa-miR-29b-3p
mimic with mature miR sequence: 5-UAGCACCAUUUGAAAUCAGUGUU-3 was
purchased from Thermo Scientific (Pittsburgh, PA). All other chemicals were purchased
from Sigma-Aldrich (St. Louis, MO); the cell culture reagents, reverse transcription kits,
universal master mix for qRT-PCR, and TaqMan® gene expression assays were
purchased from Life Technologies (Carlsbad, CA) unless specified.
5.2.2

Preparation of AuNPs-polyplex
To prepare AuNPs/PEI polyplex, 500 pL 0.5 mg/mL PEI (pH 7.0) was added to

500 pL 0.01 wt% of AuNPs. The original citric acid terminated surface of AuNPs
facilitated the deposition of PEI molecules through electrostatic interactions. The
incubation was performed at room temperature for 20 min and the extra PEI was removed
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by centrifuging at 15,000 * g for 10 min. The PEI-coated AuNPs were resuspended in
desirable amount of PBS (pH 7.0) and desirable amount of siRNA/miR29b was added to
AuNPs/PEI. The resulting mixture was mixed by pipetting and further incubated at room
temperature for 20 min.
5.2.3

NIH 3T3 and K562 Cell Culture
NIH 3T3 cells were obtained from American Type Cell Culture (ATCC,

Manassas, VA). They were grown and maintained in high-glucose DMEM supplemented
with 10% newborn calf serum, 1% penicillin and streptomycin, 1% L-glutamine, and 1%
sodium pyruvate. For subculture, culture medium was removed and discarded first. The
cell layer was briefly rinsed with DPBS to remove the serum which contains a trypsin
inhibitor. Then 1-2 mL trypsin-EDTA was added for a 100 cm2 Petri dish. Cell culture
was then observed under an inverted microscope until cell layer was dispersed (usually 515 min); 8 to 9 mL complete growth medium was added and cells were aspirated by
gently pipetting. Appropriate aliquot o f the cell suspension was transferred to a new
culture dish with the addition of more growth medium to make a total volume of 10 mL
for a 100 cm2 surface. K562 lymphoblast cells were also obtained from American Type
Cell Culture (ATCC, Manassas, VA). K562 cells were cultured and maintained in RPMI
1640 media supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100
U/mL penicillin, 100 g/mL streptomycin, and L-glutamine. For the subculture, a desired
amount of K562 cell suspension was transferred to a new Petri dish with the addition of
an appropriate amount o f fresh culture medium. All cultures were maintained at 37 °C
with 5% CO2 and 100% relative humidity.
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5.2.4

Electroporation Setup and Procedure
NIH 3T3 or K562 cells were counted with hemocytometer to determine cell

density, centrifuged at 200 x g for 5 min and then resuspended in fresh GIBCO OPTIM EM I (a serum free medium) at desired densities of 0.5 * 106 to 0.5 * 107 cells/mL.
Cell suspensions were then mixed with AuNP-polyplexes o f various concentrations and
sizes while the amount of DNA plasmids was fixed at 25 (ig / sample. Electroporation
was done with a commercial instrument (ECM 830, Harvard Apparatus) in cuvettes with
a 2-mm gap, each containing a 100 pL sample solution. The standard electroporation
condition (single 10 ms pulses o f 125 V/2 mm cuvette) was applied with a single unipolar
pulse. After electroporation, samples were transferred to 6-well cell culture plates,
incubated in a fresh medium for another 24 h, and then harvested for analysis.
5.2.5

Measurements of Cell Viability
The cell viability was evaluated by an MTS cell proliferation assay (Promega,

Madison, WI). Briefly, the cells in 100 gL/well o f medium were transferred to a 96-well
plate and incubated. Twenty microliters of CellTiter 96 AQueous One solution (Promega,
Madison, WI) was added to each well and cells were incubated at 37 °C for another 1 h.
Absorbance was measured at 492 nm on an automated plate reader (Elx 800, Biotek,
VT). Normally grown cell samples were used as negative control whose viability was set
to 100%. Data points were represented as the mean ±SD of triplicates, unless otherwise
indicated.
5.2.6

AuNPs-polvplex Delivery Efficiency of Small Interfering RNA
The GFP down regulation efficiency was determined by Agilent 2100

Bioanalyzer (Agilent Technologies, Santa Clara, CA). The fluorescence intensity o f GFP
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was measured using Cell Assay Module with live cells stained with
carboxynaphthofluorescein (CBNF). The results were analyzed with Agilent 2100 Expert
Software and 500-1500 events were counted for each sample. The Luc-siRNA down
regulation efficiency was quantified by One-Glo™Luciferase assay system (Promega,
Madison, WI). Hundred microliters One-Glo™ reagent was added to the cell growth in
100 pL o f the medium in a 96-well plate. Luminescence was measured with a plate
reader (FLUOstar OPTIMA, BMG LABTECH, Germany) after 10 min incubation at
room temperature for complete cell lysis.
5.2.7

AuNPs-polvplex Delivery Efficiency o f microRNA
The miR29b delivery efficiency was evaluated from two aspects: 1) expression of

mature miR29b; 2) expression of target genes including CDK6, DNMT3B and MCL1. To
measure expression levels, the total RNA was first transcribed into cDNA and qRT-PCR
was conducted. The expression was determined by the AACt method and normalized to
endogenous controls.
5.2.7.1

Total RNA Extraction
Total RNA was extracted using TRIzol® reagent (Life Technologies, Carlsbad,

CA). Cells were harvested by centrifugation and culture media was removed, and 0.75
mL TRIzol® reagent was added to every 0.25 mL sample (containing approximately 5-10
x 106 cells). Samples were lysed by pipetting up and down several times and incubated
for 5 min at room temperature, allowing the nucleoprotein complex to dissociate
completely. 0.2 mL chloroform was added to every 1 mL TRIzol® reagent and the tubes
were shaken vigorously for 15 s followed by 2-3 min incubation at room temperature.
Then centrifugation with 12,000 * g for 15 min at 4 °C was conducted and the samples
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were separated into a colorless upper phase, an interphase and a lower red chloroform
phase. The upper aqueous phase was transferred into new tubes by gentle pipetting
without drawing any of the interphase, and 0.5 mL 100% isopropanol for every lmL
TRIzol® reagent was added to the aqueous phase, followed by 10 min incubation at room
temperature. Centrifugation at 12,000 x g for 10 min at 4 °C was conducted and
supernatant was removed. To wash the RNA pellet, 1 mL 75% ethanol per 1 mL TRIzol®
reagent was used. Samples were vortexed briefly and centrifuged at 7500 * g for 5 min at
4 °C. We discarded the supernatant was discarded and air dried the RNA pellet for 5-10
min; 20-50 pL RNase-free water was added and samples were incubated at 55-60 °C for
10-15 min. Then the RNA was ready for downstream application.
5.2.7.2

Reverse Transcription PCR
The TaqMan® microRNA Reverse Transcription Kit (Life Technologies,

Carlsbad, CA) was used for miRNAs reverse transcription. The reagents were first
allowed to thaw on ice. The total volume of 15 pL reaction was prepared in a
polypropylene tube, including 0.15 pL dNTP mix (100 mM total), 1 pL Multiscribe™
RT enzyme (50 U/pL), 1.5 pL 10X RT buffer, 0.19 pL RNase inhibitor (20 U/pL), 4.16
pL nuclease free water, 3 pL primer and 5 pL RNA sample (1 to 10 ng). The thermal
cycler was programmed as follows: 30 min at 16 °C, 30 min at 42 °C, 5 min at 85 °C and
finally hold at 4 °C.
The High-Capacity cDNA Reverse Transcription Kit (Life Technologies,
Carlsbad, CA) was used to reverse transcribed mRNAs of CDK6, DNMT3B and MCL1.
The total volume o f 20 pL reaction was prepared in a polypropylene tube, including 2 pL
10 X RT buffer, 0.8 pL dNTP mix (100 mM), 2 pL 10 X RT random primers, 1 pL
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MultiScribe™ reverse transcriptase, 4.2 pL nuclease free water, and 10 pL RNA sample.
The thermal cycler was programmed as follows: 10 min at 25 °C, 120 min at 37 °C, 5 min
at 85 °C and finally hold at 4 °C.
5.2.7.3

qRT-PCR Amplification
The resulting cDNA from reverse transcription reaction was amplified by qRT-

PCR with TaqMan® Universal Master Mix II (Life Technologies, Carlsbad, CA). The
total volume of 20 pL reaction was prepared in a polypropylene tube, including 10 pL 2
X TaqMan® Universal Master Mix n, 1 pL 20 X TaqMan® assay and 9 pL cDNA
template (1-100 ng). The thermal cycler was programmed as follows: 10 min at 95 °C for
polymerase activation, then 40 PCR cycles with 15 s at 95 °C for denature and 1 min at
60 °C for anneal. The relative gene expression was determined by the AACt method. The
mature miR-29b expression was normalized to endogenous control RNU48 and relative
to the untreated control cells. The expression of CDK6, DNMT3B, and MCL1 mRNAs
was normalized to endogenous controlled GAPDH and relative to the untreated
controlled cells.
5.3
5.3.1

Results and Discussion

Gold Nanoparticle-Enhanced siRNA Delivery
To demonstrate the effectiveness o f AuNPs electroporation on siRNA delivery,

we chose siRNA with specific sequences to silence the expression o f GFP when
cotransfecting with pGFP by electroporation. K562 cells were cotransfected with 5 pmol
siRNA and 10 ug pMaxGFP by electroporation, together with free 10 nm AuNPs. The
bulk electroporated cells (BTX) were used as negative control. As shown in Figure 5-1 A,
less GFP expression was seen when codelivering pMaxGFP and the corresponding
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siRNA. Electroporation with AuNPs turned off more GFP expressions than
electroporation with free siRNA (Figure 5-IB).
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Figure 5-1: AuNPs electroporation enhanced siRNA delivery: (A) fluorescence images
and (B) intensity measurement on GFP expression level, n = 3 and (***) represents p <
0 . 001 .
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The enhancement of AuNPs-polyplex to siRNA interference performance should
be better than what was shown in Figure 5-1. The presence of AuNPs enhanced the
expression level of green fluorescent protein with the same mechanism demonstrated in
Figure 4-7 o f Chapter 4. This enhanced expression means siRNA with AuNPs must shut
off more GPF proteins than that using siRNA only to reach the similar protein expression
level. Therefore, the enhancement of AuNPs to siRNA down regulation is better than
what was shown in Figure 5-1 for their higher starting protein level.
5.3.2

Gold Nanoparticle-Enhanced mi RNA Delivery
K562 cells were electroporated with fluorescent AuNPs (FNP) or transferrin

grafted AuNPs (Au-Tf), together with 200 pmol miR-29b. The bulk electroporated cells
(BTX) were used as negative control. The cells that were transfected with
Lipofectamine2000 (lipo) was used as the positive control. Compared to negative control,
the mature miR-29b expression was increased ~1.45 folds in the cells that were
electroporated with FNP, and ~1.97 folds in those that were electroporated with Au-Tf at
24 hours after electroporation. This increase demonstrated that both free AuNPs and
transferrin-grafted AuNPs have enhanced miR-29b expression (Figure 5-2A). As shown
in Figure 5-2B, the expression of targeted genes DNMT3B and MCL-1 was more
efficiently down-regulated in the cells electroporated with FNP and Au-TF compared to
Lipofectamine2000 transfection. Moreover, the down regulation o f the target genes is
either more efficient or comparable with bulk electroporation (Figure 5-2B).
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Figure 5-2: Preliminary result for AuNPs enhanced miR-29b delivery in K562 cells:
(A) mature miR-29b expression (all expression levels were normalized to bulk
electroporation) (B) targeting genes expression.
5.3.3

siRNA Delivery bv AuNPs-polvplex
To demonstrate the effectiveness o f AuNPs-polyplex electroporation on siRNA

delivery, we chose siRNA with specific sequences to silence the expression of GFP and
luciferase when cotransfecting with pGFP and pLuc by electroporation. Both adherent
cells NIH 3T3 and suspension cells K562 were used for the tests.

As shown in Figure 5-3A and Figure 5-4A, less GFP expression was seen when
codelivering pMaxGFP and the corresponding siRNA. Electroporation with AuNPspolyplex (siRNA) turned off more GFP expressions than electroporation with free siRNA
(Figure 5-3B and Figure 5-4B). Similar down regulation performance was found when
cotransfecting pLuc and the corresponding siRNA GL3 into K562 cells, as shown in
Figure 5-4C. Compared to the interference result of free siRNA GL3, an additional 15%
drop of luciferase signal was found when siRNA molecules were conjugated in AuNPspolyplex. Because siRNA have a much smaller size than plasmid DNA, delivery of
neither free siRNA nor AuNPs-polyplex to cell cytosol through electroporation is very
challenging. However, because siRNA rapidly denatures, studies of siRNA delivery often
focus on their protection from enzyme degradation. Therefore, siRNA delivery with
AuNPs-polyplex electroporation could be more beneficial when used for in vivo delivery.
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Figure 5-3: AuNPs-polyplex electroporation enhanced siRNA delivery in 3T3 cells:
(A) fluorescence images and (B) intensity measurement on GFP expression level, n = 3
and (*) represents p < 0.05, (***) represents p < 0.001.
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Figure 5-4: AuNPs-polyplex electroporation enhanced siRNA delivery in K562 cells:
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(***) represents p < 0.001.
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As cotransfection of DNA plasmids and siRNA approach were adopted here, the
interference o f siRNA to the expression o f the targeting reporter gene occurs
simultaneously with that particular transgene expression in cells. The early presence of
copious siRNA probes could silence the cotransfected targeting genes more efficiently
than those that already maintain a sustained expression level in the cells. Therefore, both
free siRNA and siRNA from AuNPs-polyplex showed efficient down regulation
performance here, which allows only limited room for AuNPs-polyplex to further
enhance this interference. Moreover, the presence o f AuNPs during polyplex (siRNA)
delivery simultaneously enhanced the expression level of green fluorescent protein or
luciferase with the same mechanism demonstrated in Figure 4-7 of Chapter 4. This
enhanced expression means siRNA molecules in AuNPs-polyplex must shut off more
GPF or luciferase proteins than that using free siRNA to reach the similar protein
expression level. In other words, the enhancement o f AuNPs-polyplex to siRNA down
regulation is better than what was shown in Figure 5-3 and Figure 5-4 for their higher
starting protein level than that using free siRNA probes.
5.3.4

miRNA Delivery bv AuNPs-polvplex
As shown in Figure 5-5A, higher mature miR-29b expression was achieved with

AuNPs-polyplex electroporation. At 24 hours after electroporation, the mature miR-29b
expression was ~2.7 folds more efficient than bulk electroporation, and ~82 folds more
efficient than the expression for the sample in which the cells were incubated with
AuNPs-polyplex without electroporation. This result indicates that both AuNPs-polyplex
and electroporation contributed in the process of the miR-29b delivery. The expression of
the targeted genes, DNMT3B, CDK6, and MCL-1 was more efficiently down regulated
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with AuNPs-polyplex electroporation. As shown in Figure 5-5B, for cells that were
electroporated with AuNPs-polyplex, the target genes DNMT3B, CDK6 and MCL-1
were down-regulated by 55%, 12%, and 40%, respectively, compared to the untreated
cells, and 45%, 34%, and 35%, respectively, compared to the incubation only group.
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5.4

Conclusions

This chapter focuses on the small nucleotide delivery with the AuNP-polyplex
electroporation method. AuNPs are used to enhance the strength of the local electric field
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and conjugate with the polyplex to reduce the cytotoxicity during electroporation. The
RNA release, expression, and their effect to regulate the target genes were justified.
Based on the higher expression efficiency of the AuNP-polyplex electroporation, we
concluded that this method performs better than bulk electroporation and sole AuNP
enhanced electroporation. These findings suggest favorable prospects for the practiced
application o f small nucleotide in genetic therapies. Unlike plasmids, the RNAs are rather
fragile and the protections to prevent the RNAs from degrading in the process of delivery
are necessary. We expect that our AuNP-polyplex provide a tool for in vivo genetic
regulation with low toxicity and high delivery efficiency, and therefore serve as resource
for novel therapies in regenerative medicine.

CHAPTER 6
CONCLUSIONS AND FUTURE WORK

6.1

Conclusions

Electroporation is an effective nonviral cell transfection approach for its balance
on the transfection efficiency and cell viability, no restrictions o f probe or cell type, and
operation simplicity. In this dissertation, we investigated the improvement of
electroporation performance through the introduction of AuNPs, transferrin grafted
AuNPs, or AuNP polyplexes. Results are concluded as follows:
With the application of highly conductive AuNPs in electroporation solution, we
demonstrated better DNA and RNA delivery efficiency and higher cell viability in
mammalian cell electroporation. By adding free AuNPs in the electroporation system, we
reduced the resistance of the electroporation solution so that the local pulse strength on
the cells was enhanced. We have confirmed the pulse strength focusing effect and
investigated its dependence on the particle size, concentration, and electroporation
conditions. Transferrin-grafted AuNPs were brought to the cell membrane by affinity
binding to TfR receptors to work as virtual microelectrodes to porate cells with a limited
area from many different sites. The contributions o f localized electroporation with TfAuNPs were then evidenced. An equivalent mixture of free AuNPs and Tf-AuNPs
exhibited the best enhancement, where the transfection efficiency increased 2-3 folds
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with minimum sacrifice of cell viability. These concepts enhanced in vitro delivery of
DNA probes for both batch-type and flow-through electroporation systems.
We have also used AuNPs as carriers for PEI-DNA and PEI-RNA polyplex while
electroporation was applied for fast and direct cytosolic delivery. In this case, cationic
polymer molecules condense and/or protect genetic probes as usual, while the AuNPs
help in aggregating and fixing polycations. The AuNP fixing helps to minimize the
cytotoxicity from polyplex after cytoplasmic release without degrading probe protection.
It also avoids the poor nanoparticle quality problem existing in traditional polyplex
synthesis, namely oversized particles and broad size variations, by managing molecule
interactions and assembly on the surface of AuNPs. This hybrid approach was evaluated
with both model anchor cells (i.e., NIH/3T3) and suspension cells (i.e., K562). We found
that AuNP-polyplex showed 1.5-2 folds improvement on the transfection efficiency with
no significant increase of toxicity when compared to free plasmid delivery by
electroporation alone.
6.2

Future Work

It has been demonstrated by several studies that microRNAs are actively involved
in tumor development by functioning as tumor suppressors or/and oncogenes. Currently,
miRNA-based therapy faces several challenges, including lack o f tissue specificity, poor
stability, and insufficient cellular uptake. AuNP polyplex can be used to protect
microRNA in electroporation therapy by enhancing their intracellular stability. The
availability o f versatile surface modification technologies for AuNPs allows for great
opportunities to use AuNPs-polyplex to deliver miRNA with cell or tissue specificity.
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Gold nanomaterials have been widely used in sensing, imaging, diagnosis, and
therapeutic applications. In this case, our approaches could be integrated with some
diagnostic and therapeutic functions in a single nanosystem. Therefore, they could be
used to noninvasively track the target therapeutic probes and to measure their delivery
performance simultaneously.
The main objective of this dissertation thesis is to develop AuNPs carriers for
electroporation-based therapeutic gene-delivery. Animal models should be used to
investigate the in vivo behaviors of the therapeutic delivery, such as stability of
therapeutic probes, toxicity of the delivered complex, route tracking and clearance rate of
AuNPs.
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